<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sideroblastic anemias: Diagnosis and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sideroblastic anemias: Diagnosis and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sideroblastic anemias: Diagnosis and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sylvia S Bottomley, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert T Means, Jr, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1524133059"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The sideroblastic anemias comprise a wide spectrum of relatively uncommon heritable and acquired erythropoietic disorders that are due to various abnormalities in heme synthesis and mitochondrial function  (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>In many of these disorders, the severity of the anemia is quite variable; it is uncommon for the peripheral blood findings to be characteristic. Thus, sideroblastic anemia should be considered in all children and adults with anemia of any severity when it is unexplained by the patient's history, clinical examination, and basic laboratory data.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The singular feature that typifies all forms of sideroblastic anemia is the presence of ring sideroblasts in the bone marrow aspirate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical course and management of these heterogeneous disorders are highly dependent on the underlying cause.</p><p></p><p>An approach to the patient with evident sideroblastic anemia is discussed here, along with distinguishing clinical features, diagnostic evaluation, and management. Comprehensive discussions of the inherited and acquired sideroblastic anemias, including genetic defects and pathophysiology, are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias"</a>.)</p><p class="headingAnchor" id="H24895186"><span class="h1">CONGENITAL SIDEROBLASTIC ANEMIAS</span></p><p class="headingAnchor" id="H62076531"><span class="h2">Overview of inherited disorders</span><span class="headingEndMark"> — </span>The congenital sideroblastic anemias are inherited diseases of mitochondrial dysfunction and can be attributed to pathogenic variants in genes involved in three interrelated mitochondrial pathways: </p><p class="bulletIndent1"><span class="glyph">●</span>Heme biosynthesis</p><p class="bulletIndent1"><span class="glyph">●</span>Iron-sulfur cluster biogenesis</p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial protein synthesis and respiration</p><p></p><p>The incidence of congenital sideroblastic anemias is unknown. While they usually present in childhood, there may be cases in which these conditions are not diagnosed until adolescence or adulthood, owing to a wide spectrum of manifestations in some disease types, especially if their presentation is mild and thus delayed. (See <a class="local">'Diagnostic approach'</a> below.)</p><p>Inherited sideroblastic anemias include nonsyndromic and syndromic disorders  (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsyndromic</strong> – The nonsyndromic forms present with anemia but lack other clinical manifestations. X-linked sideroblastic anemia (XLSA) is the most common (see <a class="local">'X-linked sideroblastic anemias'</a> below), followed in prevalence by the autosomal nonsyndromic <em>SLC25A38</em> anemia [<a href="#rid1">1</a>]. (See <a class="local">'Autosomal recessive forms'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic</strong> – The syndromic inherited sideroblastic anemias are rare and include XLSA with ataxia (XLSA/A) and an X-linked MLASA variant, several autosomal recessive disorders, and two mitochondrially inherited forms.</p><p></p><p>Children with severe disease may have impaired growth and development. Many patients eventually develop systemic iron overload, management of which is discussed below. (See <a class="local">'Iron overload'</a> below.)</p><p>The inherited sideroblastic anemias are not associated with a predisposition to leukemia.</p><p class="headingAnchor" id="H15571650"><span class="h2">X-linked sideroblastic anemias</span><span class="headingEndMark"> — </span>X-linked sideroblastic anemia (XLSA) is the most common congenital sideroblastic anemia. A typical presentation is of a young boy, perhaps slightly small for age, with no other clinical features and no family history of anemia, who presents with a hemoglobin of 7 g/dL, mean corpuscular volume (MCV) of 65 fL, and a red cell distribution width (RDW) of 30. He has no evidence of iron deficiency or thalassemia. The peripheral smear shows marked hypochromia and microcytosis occasionally with inclusions. The bone marrow aspirate shows abundant ring sideroblasts.</p><p>XLSA is viewed as an X-linked recessive disorder. However, in contrast to many X-linked disorders that present predominantly in males, up to one-third of cases of XLSA occur in females, with anemia onset typically at middle age or later. This high incidence in females relative to other X-linked disorders is attributed to acquired skewed X-chromosome inactivation in hematopoietic cells with advancing age. Some experts have suggested that the terms dominant and recessive not be used for X-linked disorders because of their extraordinarily variable expressivity and the multiple mechanisms that can result in expression of X-linked traits in females, including cell autonomous expression, skewed X-inactivation, clonal expansion, and somatic mosaicism [<a href="#rid2">2</a>].</p><p>XLSA is caused by heterozygous pathogenic variants in the <em>ALAS2</em> gene, which encodes the erythroid-specific form of the heme biosynthetic enzyme 5-aminolevulinate synthase (also called delta-aminolevulinic acid synthase [ALAS])  (<a class="graphic graphic_figure graphicRef117995" href="/z/d/graphic/117995.html" rel="external">figure 1</a>). Because <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> is the essential cofactor of this enzyme, the anemia may respond to vitamin B6 supplements by enhancing the impaired function of certain <em>ALAS2</em> variants. Among all types of sideroblastic anemia, this response to vitamin B6 is thus unique to XLSA. The pathophysiology of XLSA is discussed in more detail separately.</p><p>The anemia in XLSA is of quite variable severity. It is always microcytic in males but normocytic or macrocytic in most females. The explanation for this difference is that in females, skewed X-chromosome inactivation in hematopoietic cells in the bone marrow leads to predominantly nonviable red blood cell (RBC) precursors usually bearing a severe mutant <em>ALAS2</em> allele (that succumb to intramedullary hemolysis), while the peripheral blood RBCs represent the progeny of the RBC precursors bearing the normal <em>ALAS2</em> allele, which undergo accelerated release from the bone marrow, mediated by increased erythropoietin drive of anemic hypoxia. This often produces macrocytosis [<a href="#rid3">3,4</a>].</p><p>In cases where the anemia is mild, the condition may not be discovered until later in life and may be attributed to a myelodysplastic syndrome (MDS) or thalassemia [<a href="#rid5">5-7</a>]. </p><p>The severity of the anemia usually remains stable over many years; however, in some individuals, it worsens over time. Disease worsening over time may be attributed to one or more of the following, several of which relate to reduced <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> (pyridoxine) availability (for XLSA that responds to vitamin B6 supplementation):</p><p class="bulletIndent1"><span class="glyph">●</span>Discontinuation of <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> that had been part of a multivitamin preparation the patient no longer takes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Changes in dietary habits that lead to reduced intake of <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age-associated alterations in <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> metabolism</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age-associated skewing of the X chromosome inactivation pattern (lyonization) in hematopoietic cells in women, leading to progressive inactivation of the normal <em>ALAS2</em> allele and greater relative expression of the allele bearing the pathogenic variant [<a href="#rid3">3,8-11</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The commonly associated iron overload, which may further impair erythroblast mitochondrial function and heme synthesis [<a href="#rid12">12</a>]</p><p></p><p>XLSA with ataxia (XLSA/A) is a syndromic X-linked disorder caused by pathogenic variants in a different gene, <em>ABCB7,</em> which encodes an ATP-binding cassette with a postulated role in exporting iron-sulfur clusters (ISC) from mitochondria for cytosolic ISC-containing proteins [<a href="#rid13">13</a>]. The anemia is microcytic and relatively mild. Neurologic findings include delayed motor and cognitive development, incoordination, and nonprogressive cerebellar atrophy [<a href="#rid13">13-16</a>]. (See  <a class="medical medical_review" href="/z/d/html/6234.html" rel="external">"Overview of the hereditary ataxias", section on 'X-linked sideroblastic anemia with ataxia'</a>.)</p><p>A second syndromic X-linked congenital sideroblastic anemia is associated with a mutation in <em>NDUFB11</em>, which encodes a mitochondrial respiratory complex I associated protein [<a href="#rid17">17,18</a>]. The anemia is normocytic and moderately severe. Associated features have been variable among patients, such as short stature or developmental delay or myopathy.</p><p class="headingAnchor" id="H3539765344"><span class="h2">Autosomal recessive forms</span><span class="headingEndMark"> — </span>Autosomal recessive congenital sideroblastic anemias (ARCSA) include nonsyndromic and syndromic forms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsyndromic forms</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ARCSA due to pathogenic variants in <em>SLC25A38</em>, which encodes the mitochondrial glycine transporter protein</p><p class="bulletIndent2"><span class="glyph">•</span>ARCSA due to variants in <em>HSPA9</em>, which encodes a mitochondrial protein involved in iron-sulfur cluster (ISC) production</p><p class="bulletIndent2"><span class="glyph">•</span>ARCSA due to variants in <em>HSCB</em>, which encodes a mitochondrial co-chaperone protein for HSPA9 involved in ISC production</p><p class="bulletIndent2"><span class="glyph">•</span>ARCSA due to variants in <em>GLRX</em>, which encodes glutaredoxin 5, a mitochondrial enzyme required for ISC formation</p><p class="bulletIndent2"><span class="glyph">•</span>Erythropoietic protoporphyria (EPP) due to variants in <em>FECH</em>, which encodes the terminal enzyme of heme biosynthesis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic forms</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD), due to pathogenic variants in <em>TRNT1</em> </p><p class="bulletIndent2"><span class="glyph">•</span>Myopathy, lactic acidosis, and sideroblastic anemia (MLASA), due to variants in <em>PUS1</em> or <em>YARS2</em>; and three clinical variants due to pathogenic variants in <em>LARS2</em>, <em>IARS1</em>, or <em>SARS2 </em></p><p class="bulletIndent2"><span class="glyph">•</span>Thiamine-responsive megaloblastic anemia (TRMA), associated with diabetes mellitus and deafness, due to pathogenic variants in <em>SLC19A2</em> </p><p></p><p><em>TRNT1</em>, <em>PUS1</em>, <em>YARS2</em>, <em>LARS2, IARS1</em>, and <em>SARS2</em> encode components of the mitochondrial protein translation apparatus. <em>SLC19A2</em> encodes the high-affinity <a class="drug drug_general" data-topicid="9988" href="/z/d/drug information/9988.html" rel="external">thiamine</a> transporter. The roles of these proteins in the pathogenesis of anemia and other disease manifestations are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias"</a>.)</p><p>Patients with pathogenic variants of <em>SLC25A38</em> invariably have severe microcytic anemia that presents in early childhood, or occasionally in young adults, and nearly always requires chronic transfusion support [<a href="#rid1">1</a>]. While patients with variants in <em>TRNT1</em> were all first noted to present with severe microcytic, transfusion-dependent anemia, subsequent experience has revealed a much wider spectrum of clinical manifestations as well as disease severity including absence of anemia [<a href="#rid19">19</a>]. Moreover, this syndrome can be considered the third most prevalent among the inherited sideroblastic anemias. </p><p>Patients with <em>HSPA9</em> and <em>HSCB</em> pathogenic variants have mild or moderate microcytic anemia. Variants in <em>GLRX5</em>,<em> PUS1</em>,<em> YARS2</em>,<em> LARS2</em>, <em>IARS2, SARS2, </em>and<em> SLC19A2 </em>cause moderate to severe anemia. Variants in <em>FECH</em> cause EPP, which is associated with mild microcytic anemia, but the incidence of the ring sideroblast feature is not known as it was observed in only a small series of patients and not in others. As the name implies, TRMA responds to <a class="drug drug_general" data-topicid="9988" href="/z/d/drug information/9988.html" rel="external">thiamine</a> supplementation. (See <a class="local">'Treatments for anemia'</a> below.)</p><p class="headingAnchor" id="H1935314133"><span class="h2">Mitochondrially inherited forms</span><span class="headingEndMark"> — </span>Two of the syndromic forms follow a mitochondrial inheritance pattern:</p><p class="bulletIndent1"><span class="glyph">●</span>Pearson marrow-pancreas syndrome, associated with acidosis and pancreatic insufficiency, due to large-scale mitochondrial DNA (mtDNA) deletions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia variant (MLASA-plus), due to heteroplasmic pathogenic variant in <em>MTATP6</em> </p><p></p><p>In both of these syndromes, the anemia is normocytic or macrocytic, usually but not always severe, and typically transfusion dependent.</p><p>Pearson marrow-pancreas syndrome is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'Pearson syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Pearson syndrome (large deletion of mitochondrial DNA)'</a> and  <a class="medical medical_review" href="/z/d/html/5877.html" rel="external">"Overview of the causes of chronic diarrhea in children in resource-abundant settings", section on 'Pancreatic exocrine insufficiency'</a> and  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants", section on 'Mitochondrial disorders'</a>.)</p><p class="headingAnchor" id="H750627791"><span class="h1">ACQUIRED SIDEROBLASTIC ANEMIAS</span></p><p class="headingAnchor" id="H3805562417"><span class="h2">Overview of acquired disorders</span><span class="headingEndMark"> — </span>Acquired sideroblastic anemias may be discovered incidentally or may come to medical attention in the setting of nonspecific symptoms of anemia or neurologic findings. There are two principal categories  (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Clonal sideroblastic anemias, which are bone marrow stem cell disorders that are classified within the broad rubric of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). (See <a class="local">'MDS/MPN variants'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In sideroblastic anemia attributed to copper deficiency, certain medications, or excessive alcohol use, the anemia is fully reversible upon removal of the cause. In the reversible forms of acquired sideroblastic anemia, the clinical setting characterizes the problem. The prevalence of these disorders is not well characterized. (See <a class="local">'Copper deficiency'</a> below and <a class="local">'Medications'</a> below and <a class="local">'Excessive alcohol'</a> below.)</p><p></p><p>Additional information about the mechanisms of these disorders is presented separately.</p><p class="headingAnchor" id="H3370785817"><span class="h2">MDS/MPN variants</span><span class="headingEndMark"> — </span>Clonal sideroblastic anemias, also referred to as MDS/MPN variants, are the most common sideroblastic anemias in clinical practice, almost always occur in individuals over age 40, and fall into the lower-risk MDS categories in the International Prognostic Scoring System (IPSS). Other causes of acquired sideroblastic anemia should be excluded (eg, copper deficiency, medications), as well as X-linked sideroblastic anemia (XLSA) in females that is nearly always indistinguishable from the MDS/MPN variants. (See <a class="local">'Diagnostic approach'</a> below.)</p><p>Three of the MDS or MPN variants are associated with ring sideroblasts. Their names were updated in the 2016 World Health Organization (WHO) classification of hematopoietic neoplasms as follows [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS-RS-SLD</strong> – MDS with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD); this was previously called refractory anemia with ring sideroblasts (RARS). These individuals have normal white blood cell (WBC) and platelet counts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS-RS-MLD</strong> – MDS with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD); this was previously called refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS). These individuals have low WBC and/or platelet counts and may have the pseudo-Pelger-Huët anomaly  (<a class="graphic graphic_picture graphicRef71990" href="/z/d/graphic/71990.html" rel="external">picture 1</a>) or immature WBCs in the peripheral blood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS/MPN-RS-T</strong> – MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T); this was previously called refractory anemia with ring sideroblasts and thrombocytosis (RARS-T). These patients have thrombocytosis with or without leukocytosis and frequently have the <em>JAK2</em> V617F mutation that is found in other myeloproliferative neoplasms [<a href="#rid21">21,22</a>]. MDS/MPN-RS-T is the least common of the clonal sideroblastic anemias.</p><p></p><p>The anemia typically develops insidiously and may present as an incidental finding or when the individual develops symptoms of anemia such as fatigue, dyspnea, or reduced exercise tolerance. Older adults, especially those with coexisting coronary artery disease, may present with angina or other symptoms of myocardial ischemia. On examination, patients may have pallor and/or hepatosplenomegaly (found in up to one-third to one-half of patients). With advanced iron overload, often accentuated by repeated transfusions, symptoms and signs of liver decompensation, as well as heart failure and arrhythmia, may occur.</p><p>The anemia is usually moderate and normocytic or macrocytic, with a variable population of hypochromic cells on the peripheral blood smear. Particularly characteristic are occasional siderocytes (hypochromic red cells with basophilic granules that stain positive for iron); the granules are referred to as Pappenheimer bodies  (<a class="graphic graphic_picture graphicRef51160" href="/z/d/graphic/51160.html" rel="external">picture 2</a>). The WBC and platelet counts may be normal, increased, or reduced, depending on the MDS variant.</p><p>The principal clinical problem in these clonal disorders is anemia when it progresses. Its management is discussed below and in a separate topic review. (See <a class="local">'Agents for MDS/MPN variants'</a> below and  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)"</a>.)</p><p>Acquired heterozygous missense mutations in splicing factor 3B, subunit 1 (<em>SF3B1</em>), which encodes a constituent of the messenger RNA (mRNA) spliceosome, are found in up to 85 percent of patients with any of the three MDS/MPN variants. Their presence confirms the diagnosis of one of these variants and excludes XLSA in women; it also appears to impart a favorable clinical outcome [<a href="#rid22">22,23</a>]. How the <em>SF3B1</em> mutations lead to the ring sideroblastic phenotype remains to be elucidated. Evidence shows that only the MDS-RS-MLD variant is at risk of transformation to acute leukemia [<a href="#rid23">23-25</a>]. (See  <a class="medical medical_review" href="/z/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults", section on 'Others'</a>.)</p><p class="headingAnchor" id="H2175996082"><span class="h2">Copper deficiency</span><span class="headingEndMark"> — </span>Copper deficiency can cause sideroblastic anemia that may be misdiagnosed as an MDS variant. The deficiency may develop in a number of clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malabsorption</strong> – Typically malabsorption occurs in the setting of small bowel disorders or gastrointestinal surgery [<a href="#rid26">26-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of supplementation</strong> – Deficiency can develop with prolonged <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> or forced enteral feeding if copper is not included in the formulations [<a href="#rid33">33-37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zinc ingestion</strong> – Causes of zinc-induced copper deficiency include prolonged ingestion of zinc supplements, use of large amounts of denture cream containing zinc, or massive and prolonged ingestion of zinc-containing coins associated with psychiatric illness (metal pica) [<a href="#rid38">38-46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chelation</strong> – Use of the copper-chelating agent <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> (triethylene tetramine dihydrochloride; TTH) can cause copper deficiency [<a href="#rid47">47</a>]. (See <a class="local">'Medications'</a> below.)</p><p></p><p>The mechanism of copper deficiency after ingestion of excess zinc has been attributed to induction of the intestinal metal-binding protein metallothionein by zinc [<a href="#rid48">48</a>]. Metallothionein preferentially binds copper in the gut and prevents its absorption, thereby enhancing its excretion in sloughed intestinal cells and leading to clinical copper deficiency. A case report has also described copper deficiency in an infant with a familial nephrotic syndrome associated with an <em>NPHS2</em> mutation (see  <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology"</a>). The presumed mechanism was attributed to urinary losses of ceruloplasmin and copper.</p><p>The anemia due to copper deficiency is progressive and may be profound, with hemoglobin levels as low as 3.5 g/dL [<a href="#rid38">38</a>]. The anemia typically is normocytic or slightly macrocytic, but hypochromic and microcytic red cells are detectable on the blood smear.</p><p>In addition to anemia, copper deficiency can cause neutropenia and is often (if not invariably) accompanied by neurologic manifestations. Absolute neutrophil counts are generally strikingly reduced to less than 1000/microL, while the platelet count is usually normal. Pancytopenia has been reported in some cases. Neurologic manifestations are varied; myeloneuropathy is commonly seen [<a href="#rid49">49-53</a>]. Other neurologic findings are related to demyelination; peripheral and optic neuropathy have also been reported. (See  <a class="medical medical_review" href="/z/d/html/16517.html" rel="external">"Copper deficiency myeloneuropathy"</a> and <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>.)</p><p>Diagnosis of suspected copper deficiency is confirmed by serum copper and ceruloplasmin levels, which are uniformly low. In cases of zinc-induced copper deficiency, serum zinc levels are typically increased two- to threefold. Serum and urine zinc concentrations were also increased in some patients with copper deficiency and neurologic disease without identifiable excess zinc intake [<a href="#rid49">49,53</a>].</p><p>Upon bone marrow examination, some individuals with copper deficiency were misdiagnosed as having clonal sideroblastic anemia [<a href="#rid28">28,31,53</a>]. Moderate numbers of ring sideroblasts are observed, and plasma cells often contain prominent hemosiderin [<a href="#rid31">31</a>]. (See <a class="local">'Bone marrow examination'</a> below.)</p><p>The copper deficit is readily corrected with parenteral or oral copper preparations that provide 2 mg of elemental copper per day, and the hematologic abnormalities return to normal in less than two months [<a href="#rid31">31,34,38,49,53</a>]. However, this usual dose of copper may not be sufficient for all patients as relapse has occurred [<a href="#rid54">54</a>], and long-term follow-up is advised for all patients. Hematologic recovery may occur following discontinuation of excess zinc intake alone. Neurologic deficits may improve or only stabilize with continued copper supplementation [<a href="#rid31">31,49,53</a>].</p><p class="headingAnchor" id="H392548171"><span class="h2">Medications</span><span class="headingEndMark"> — </span>The antibiotics <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> (INH), <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, and <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">chloramphenicol</a> are the most commonly reported causes of drug-induced sideroblastic anemia.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a> – The incidence of anemia caused by INH appears to be quite low. However, certain individuals seem more susceptible to INH-induced anemia (eg, concomitant folate deficiency). In a series of 63 patients undergoing treatment for tuberculosis (most with INH), one had ring sideroblasts in the bone marrow but was not anemic, and an additional 19 (30 percent) had excess hemosiderin granules [<a href="#rid55">55</a>]. Occasional cases of INH-related sideroblastic anemia continue to be reported [<a href="#rid56">56,57</a>]. The mechanism of the anemia involves interference of <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> metabolism by the drug, depriving the delta-aminolevulinic acid (ALA) synthase enzyme of its essential cofactor [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">In patients with INH-induced sideroblastic anemia, anemia typically occurs within 1 to 10 months after initiation of the drug when <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> is not coadministered. It may be mild or moderate (eg, hemoglobin 7 to 8 g/dL). There is prominent hypochromia and microcytosis, with dimorphic red blood cell morphology [<a href="#rid59">59</a>]. Ring sideroblasts are present in the bone marrow. Serum vitamin B6 concentrations were subnormal in most patients [<a href="#rid60">60,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">Chloramphenicol</a><strong> and </strong><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> – The use of chloramphenicol has declined in many settings due to availability of other effective antibiotics and the known risk of potentially serious and fatal aplastic anemia, for which the drug carries a Boxed Warning. Earlier use of chloramphenicol documented that the drug regularly produced sideroblastic anemia, with moderately severe reductions in hemoglobin level, increased serum iron level, and ring sideroblasts in the bone marrow [<a href="#rid62">62,63</a>]. The drug impairs mitochondrial protein synthesis (similar to its bacteriostatic mechanism of action) [<a href="#rid64">64</a>]. Linezolid has subsequently been shown to cause a similar sideroblastic anemia [<a href="#rid65">65-67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – A number of other drugs have been implicated in causing sideroblastic anemia in a few cases [<a href="#rid47">47,58,68-71</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">Busulfan</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">Cycloserine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">Fusidic acid</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">Melphalan</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">Penicillamine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">Pyrazinamide</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">Trientine</a> (triethylene tetramine dihydrochloride [TTH]), a copper chelating agent (see <a class="local">'Copper deficiency'</a> above)</p><p></p><p class="headingAnchor" id="H3238957443"><span class="h2">Excessive alcohol</span><span class="headingEndMark"> — </span>Anemia in the setting of chronic excessive alcohol use is often multifactorial. Possible contributing factors such as associated liver disease, portal hypertension with splenomegaly, gastrointestinal bleeding with or without iron deficiency, nutritional folate deficiency, infection, and direct bone marrow toxicity by ethanol with decreased erythropoiesis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7151.html" rel="external">"Hematologic complications of alcohol use", section on 'Anemia'</a>.)</p><p>Approximately one-third of patients with alcohol-induced anemia have sideroblastic changes, with occasional siderocytes in the peripheral blood [<a href="#rid72">72</a>]. Bone marrow examination shows ring sideroblasts, which typically represent late erythroblasts. Iron studies usually show increased iron stores (eg, high ferritin, high transferrin saturation), unless there is concomitant iron deficiency (eg, due to gastrointestinal bleeding).</p><p>Withdrawal of alcohol is followed by recovery from the anemia over several weeks. The rate of improvement of the anemia depends on whether other alcohol-induced defects or associated medical illnesses (eg, bleeding, infection) are contributing to the anemia. A more prompt recovery may be associated with a brisk reticulocytosis, which might be otherwise mistaken as an episode of hemolytic anemia. Follow-up bone marrow examination would show disappearance of ring sideroblasts and increased erythropoiesis within a few days to two weeks [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H1385838383"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H1120573638"><span class="h2">Overview of diagnostic issues</span><span class="headingEndMark"> — </span>Sideroblastic anemia is often considered in the differential diagnosis of unexplained anemia after more common causes have been excluded. (See  <a class="medical medical_review" href="/z/d/html/5927.html" rel="external">"Approach to the child with anemia"</a> and  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p>The diagnosis of <strong>all</strong> sideroblastic anemias is made by identifying the telltale ring sideroblasts on the bone marrow aspirate smear. Distinction among the specific forms of sideroblastic anemia, which determines management, involves evaluation of clinical features and laboratory testing, often followed by genetic testing. The algorithm summarizes the diagnostic approach  (<a class="graphic graphic_algorithm graphicRef135067" href="/z/d/graphic/135067.html" rel="external">algorithm 1</a>).</p><p>It is worth noting that the associated clinical features in some syndromic congenital sideroblastic anemias occur variably or are not yet fully manifest at presentation to be recognized, and thus some of the inherited forms may not be correctly identified until later in life.</p><p>The causes of sideroblastic anemia are listed in the tables, categorized by whether the cause is congenital or acquired  (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>) and by whether the red blood cells (RBCs) are microcytic or normocytic/macrocytic  (<a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>). Details of the diagnostic approach according to the age range of the patient are presented in the following sections. (See <a class="local">'Child/young adult (&lt;20 years) evaluation'</a> below and <a class="local">'Adult evaluation'</a> below.)</p><p class="headingAnchor" id="H4205029427"><span class="h2">Child/young adult (&lt;20 years) evaluation</span><span class="headingEndMark"> — </span>A congenital sideroblastic anemia may be suspected based on a known family history, clinical features that suggest a syndromic condition, or lack of another diagnosis. (See <a class="local">'Overview of inherited disorders'</a> above.)</p><p>Microcytic anemia (anemia with a low mean corpuscular volume [MCV]) in the absence of iron deficiency or thalassemia is highly suggestive of a common congenital sideroblastic anemia such as X-linked sideroblastic anemia (XLSA) or <em>SLC25A38</em> anemia  (<a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>). Much less common are other autosomal recessive forms and several syndromic forms of congenital sideroblastic anemia that are microcytic or normocytic/macrocytic, while a reversible sideroblastic anemia would be extremely rare and unlikely to be encountered in a child.</p><p>The mode of transmission (X-linked or autosomal) may be helpful if it is clearly X-linked (no transmission to sons from fathers), but it is worth keeping in mind that the X-linked sideroblastic anemias can be transmitted to daughters from mothers or fathers.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsyndromic findings</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microcytic anemia</strong> – The most frequent inherited sideroblastic anemia syndrome appears to be the sideroblastic anemia with immunodeficiency, periodic fevers, and developmental delay (SIFD; due to pathogenic variants in <em>TRNT1</em>). XLSA with ataxia (XLSA/A; due to pathogenic variants in <em>ABCB7</em>) is very rare, with only six families reported since the syndrome was first described. (See <a class="local">'X-linked sideroblastic anemias'</a> above and <a class="local">'Autosomal recessive forms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normocytic or macrocytic anemia</strong> – The candidate inherited sideroblastic anemia syndromes are myopathy, lactic acidosis, and sideroblastic anemia (MLASA) or variants thereof (due to pathogenic variants in <em>PUS1</em>, <em>YARS2</em>,<em> MT-ATP6</em>, <em>LARS2</em>, <em>IARS1, SARS2, </em>or <em>NDUFB11</em>); Pearson marrow-pancreas syndrome (mitochondrial DNA deletions), which is associated with lactic acidosis and pancreatic insufficiency; or thiamine-responsive megaloblastic anemia (TRMA; due to pathogenic variants in <em>SLC19A2</em>), which is associated with diabetes mellitus and deafness. (See <a class="local">'X-linked sideroblastic anemias'</a> above and <a class="local">'MDS/MPN variants'</a> above and <a class="local">'Copper deficiency'</a> above and <a class="local">'Medications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic findings</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microcytic anemia</strong> – Although uncommon, the most frequent inherited sideroblastic anemia syndrome probably is sideroblastic anemia with immunodeficiency, periodic fevers, and developmental delay (SIFD; due to pathogenic variants in <em>TRNT1</em>). XLSA with ataxia (XLSA/A; due to pathogenic variants in <em>ABCB7</em>) is very rare, with only six families reported since the syndrome was first described. (See <a class="local">'Overview of inherited disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normocytic or macrocytic anemia</strong> – The candidate inherited sideroblastic anemia syndromes are myopathy, lactic acidosis, and sideroblastic anemia (MLASA) or variants thereof (due to pathogenic variants in <em>PUS1</em>, <em>YARS2</em>,<em> MT-ATP6</em>, <em>LARS2</em>,<em> IARS1, SARS2, </em>or <em>NDUFB11</em>); Pearson marrow-pancreas syndrome (mitochondrial DNA deletions), which is associated with lactic acidosis and pancreatic insufficiency; or thiamine-responsive megaloblastic anemia (TRMA; <em>SLC19A2</em> mutations), which is associated with diabetes mellitus and deafness. (See <a class="local">'Overview of inherited disorders'</a> above.)</p><p></p><p>These genetic disorders are ultimately confirmed by DNA analysis  (<a class="graphic graphic_algorithm graphicRef135067" href="/z/d/graphic/135067.html" rel="external">algorithm 1</a>). The clinical phenotype, including the presence of marrow ring sideroblasts, dictates which gene to prioritize for mutation analysis. Depending on the result, other likely candidate genes can be sequentially tested. (See <a class="local">'Molecular (genetic) testing'</a> below.)</p><p>However, failure to find a pathogenic variant in the known relevant genes does not eliminate the possibility of a congenital sideroblastic anemia, as causative variants have not yet been identified in up to one-third of cases [<a href="#rid74">74-76</a>]. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Congenital sideroblastic anemias'</a>.)</p><p class="headingAnchor" id="H4025036272"><span class="h2">Adult evaluation</span><span class="headingEndMark"> — </span>In adults, an acquired sideroblastic anemia is much more common than an inherited form, although the diagnosis of a congenital type has often been delayed until adulthood. The algorithm summarizes the approach  (<a class="graphic graphic_algorithm graphicRef135067" href="/z/d/graphic/135067.html" rel="external">algorithm 1</a>).</p><p>The presentations in adults are those with a clue from the history, or those for whom the bone marrow aspirate performed for unexplained anemia reveals ring sideroblasts:</p><p class="bulletIndent1"><span class="glyph">●</span>A clue from the history, such as gastrointestinal surgery, enteral or parenteral feedings without copper supplementation, or excessive zinc ingestion, suggests copper deficiency. Use of an implicated medication or evidence of excessive alcohol use may also be helpful in suggesting the cause. Uncommonly, unexplained chronic anemia may be reported in multiple family members. In these situations, the clinical setting defines which laboratory tests are performed. (See <a class="local">'Overview of acquired disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an adult over the age of 40 with ring sideroblasts in the bone marrow aspirate, the most likely diagnosis is a myelodysplastic syndrome (MDS). These conditions are diagnoses of exclusion, and reversible causes such as copper deficiency, implicated medications, and excessive alcohol use should be eliminated before the diagnosis of MDS is established. It is also prudent to exclude XLSA in all women with ring sideroblasts who are considered to have MDS, as their phenotype of XLSA is indistinguishable from MDS. An exception is an individual with one of the commonly acquired mutations in the <em>SF3B1</em> and/or the<em> JAK2 </em>gene, which confirms an MDS or myeloproliferative neoplasm (MPN) and excludes a congenital sideroblastic anemia. (See <a class="local">'MDS/MPN variants'</a> above and <a class="local">'Copper deficiency'</a> above and <a class="local">'Medications'</a> above and <a class="local">'Excessive alcohol'</a> above and <a class="local">'X-linked sideroblastic anemias'</a> above.)</p><p></p><p class="headingAnchor" id="H1188336925"><span class="h2">Laboratory and bone marrow findings</span></p><p class="headingAnchor" id="H2262170328"><span class="h3">CBC and blood smear</span><span class="headingEndMark"> — </span>Patients being evaluated for sideroblastic anemia may have prior complete blood counts (CBCs) and blood smears available for review. The white blood cell (WBC) and platelet counts are typically normal; if these are low, an explanation should be sought, such as splenomegaly with hypersplenism or MDS. The platelet count is increased in myeloproliferative neoplasms (MPN). (See <a class="local">'MDS/MPN variants'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin</strong> – The hemoglobin level is variable among the sideroblastic anemias; in the inherited forms, the hemoglobin for a given patient tends to remain constant for long periods of time. In the autosomal recessive congenital sideroblastic anemias due to pathogenic variants in <em>SLC25A38</em> or <em>TRNT1</em>, the hemoglobin is usually below 7 g/dL at diagnosis  (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RBC indices</strong> – The mean corpuscular volume (MCV) is often helpful in distinguishing among the sideroblastic anemias  (<a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>). Diagnosis stratified by MCV is illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef135067" href="/z/d/graphic/135067.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">The anemia is microcytic (low MCV) in all nonsyndromic forms of congenital sideroblastic anemia (XLSA in males and those due to pathogenic variants in <em>SLC25A38</em>, <em>HSPA9</em>, <em>HSCB</em>,<em> </em>and <em>GLRX5</em>) and two of the syndromic forms (XLSA/A and SIFD). The anemia is also microcytic in sideroblastic anemia due to <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>. The degree of microcytosis and hypochromia (reflected in the MCV and mean corpuscular hemoglobin [MCH]) generally parallels the severity of the anemia  (<a class="graphic graphic_picture graphicRef66705" href="/z/d/graphic/66705.html" rel="external">picture 3</a>).</p><p></p><p class="bulletIndent1">The anemia is normocytic to macrocytic (normal to high MCV) in females with XLSA and in most of the syndromic forms of congenital sideroblastic anemia (MLASAs, Pearson marrow-pancreas syndrome, and TRMA). The anemia is normocytic to macrocytic in nearly all of the acquired forms, including MDS, copper deficiency, and most medication-induced cases.</p><p></p><p class="bulletIndent1">In many sideroblastic anemias, a large variation in RBC size is reflected in an abnormally high red cell volume distribution width (RDW)  (<a class="graphic graphic_figure graphicRef69210" href="/z/d/graphic/69210.html" rel="external">figure 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RBC morphology</strong> – In severe cases of sideroblastic anemia, striking anisocytosis, poikilocytosis, target cells, and occasional siderocytes are prominent findings on blood smear, as depicted in the lower panel of the figure  (<a class="graphic graphic_picture graphicRef66705" href="/z/d/graphic/66705.html" rel="external">picture 3</a>). This can lead to mistaken impression of other disorders with similar findings, such as iron deficiency or thalassemia. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">Siderocytes are essentially pathognomonic of sideroblastic anemia. They are hypochromic RBCs with distinctive coarse basophilic granules, usually in pairs, which can be seen on the standard Wright or Wright-Giemsa stain  (<a class="graphic graphic_picture graphicRef51160" href="/z/d/graphic/51160.html" rel="external">picture 2</a>). These granules are residual iron-laden mitochondria, and they will stain positive for iron as Pappenheimer bodies. They represent the mature RBC counterpart of ring sideroblasts seen in the bone marrow. Siderocytes are always numerous in the unlikely event that the patient has had a splenectomy, although splenectomy <strong>is not </strong>recommended in the sideroblastic anemias. (See <a class="local">'Avoidance of splenectomy'</a> below.)</p><p></p><p class="bulletIndent1">RBC dimorphism is common, particularly in females with milder XLSA when the anemia may be microcytic by MCV [<a href="#rid9">9</a>]. This is depicted in the upper panel of the figure  (<a class="graphic graphic_picture graphicRef66705" href="/z/d/graphic/66705.html" rel="external">picture 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reticulocyte count</strong> – The reticulocyte count is normal to low, which is consistent with the associated ineffective erythropoiesis in most cases.</p><p></p><p class="headingAnchor" id="H647479520"><span class="h3">Bone marrow examination</span><span class="headingEndMark"> — </span>The bone marrow aspirate smear in sideroblastic anemia usually shows normoblastic erythroid hyperplasia and often poorly hemoglobinized cytoplasm in the RBC precursors. Dysplastic changes are common in the MDS disorders. The Prussian blue-stained smear reveals the presence of ring sideroblasts  (<a class="graphic graphic_picture graphicRef62536" href="/z/d/graphic/62536.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef65887" href="/z/d/graphic/65887.html" rel="external">picture 5</a>), the diagnostic hallmark of all sideroblastic anemias. In the common congenital sideroblastic anemias, the ring sideroblast finding is prominent in late, nondividing erythroblasts, while in the MDS disorders it is evident at all stages of erythroid maturation. (See <a class="local">'Overview of diagnostic issues'</a> above.)</p><p>Ring sideroblasts are RBC precursors (erythroblasts) in which numerous coarse siderotic (iron-containing) granules tend to surround (form a ring around) the nucleus  (<a class="graphic graphic_picture graphicRef62536" href="/z/d/graphic/62536.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef65887" href="/z/d/graphic/65887.html" rel="external">picture 5</a>). These granules represent pathologic iron deposits in mitochondria due to various aberrations in the processing of iron in the developing RBC [<a href="#rid77">77,78</a>]. This diagnostic feature became the basis for the heterogeneous sideroblastic anemias being lumped together as a group of diseases after they were recognized in the 1960s [<a href="#rid79">79</a>]. The amount of iron in bone marrow macrophages is often strikingly increased due to the presence of ineffective erythropoiesis with intramedullary hemolysis.</p><p>The ring sideroblast abnormality may be masked in the exceptional case of sideroblastic anemia with concomitant iron deficiency, most commonly encountered in young females with excess menstrual blood losses [<a href="#rid28">28,80</a>]. In such cases, iron studies show a reduced or normal serum iron and a low ferritin concentration, consistent with a concomitant iron deficiency state. Occasionally, technical reasons in performing the Prussian blue stain may account for not detecting ring sideroblasts.</p><p>It is important to recognize that ring sideroblasts are not detectable in iron-stained bone marrow biopsy sections, as the erythroblast iron becomes leeched out during the tissue processing. Thus, a simple needle aspirate of bone marrow for smears (for Wright-Giemsa and iron staining) fully suffices for the diagnostic procedure; a biopsy is unnecessary and not helpful.</p><p>Other morphologic abnormalities in the bone marrow can provide a diagnostic clue for certain sideroblastic anemias:</p><p class="bulletIndent1"><span class="glyph">●</span>Dyserythropoietic changes such as a left shift of erythroid precursors, megaloblastoid changes, chromatin clumping, and binuclearity are common in MDS variants but not in most other sideroblastic anemias, and these are associated with certain cellular marker changes detectable by flow cytometry [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytoplasmic vacuolization in early myeloid and erythroid precursors is common in Pearson syndrome  (<a class="graphic graphic_picture graphicRef118336" href="/z/d/graphic/118336.html" rel="external">picture 6</a>) and is found in MLASA due to pathogenic variants in <em>YARS2</em>  (<a class="graphic graphic_picture graphicRef118339" href="/z/d/graphic/118339.html" rel="external">picture 7</a>) [<a href="#rid82">82,83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vacuoles in erythroid and myeloid precursors are also a common finding in copper deficiency, and there may be hyperplasia of hematogones (lymphoid precursor cells) [<a href="#rid31">31,36,53</a>]. These changes are depicted in the figure  (<a class="graphic graphic_picture graphicRef108735" href="/z/d/graphic/108735.html" rel="external">picture 8</a>).</p><p></p><p class="headingAnchor" id="H998155070"><span class="h3">Iron studies</span><span class="headingEndMark"> — </span>Iron studies will often have been obtained as part of the initial anemia evaluation, and they should be obtained in individuals for whom they are not available. (See <a class="local">'Additional post-diagnosis testing'</a> below.)</p><p>At presentation (before transfusions) the serum transferrin saturation and serum ferritin are typically increased in most congenital sideroblastic anemias and in patients with MDS disorders with ring sideroblasts. </p><p>These tests are important both to assess the degree of excess iron before clinical manifestations of iron overload develop and to guide management in preventing tissue damage and associated symptoms if these are not already evident. (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H710070705"><span class="h3">Hepcidin and erythroferrone</span><span class="headingEndMark"> — </span>These hormonal mediators of intestinal iron absorption are relevant to the pathophysiology of the iron overload in anemias with ineffective erythropoiesis. Whether their measurement is clinically useful in sideroblastic anemias remains to be established. </p><p class="headingAnchor" id="H637226710"><span class="h3">Erythrocyte protoporphyrin</span><span class="headingEndMark"> — </span>The erythrocyte protoporphyrin (PP) measurement has not been systematically examined in the majority of sideroblastic anemia types and has limited value in diagnosis. RBC PP values have been established in a few forms:</p><p class="bulletIndent1"><span class="glyph">●</span>In X-linked sideroblastic anemia (XLSA) and with defects in <em>SLC25A38</em>, the erythrocyte PP level is uniformly low because heme synthesis and hence protoporphyrin production are reduced</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In XLSA with ataxia (XLSA/A), erythrocyte PP is increased (mainly as zinc protoporphyrin) [<a href="#rid13">13,14</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In MDS disorders with ring sideroblasts, erythrocyte PP is characteristically increased up to 300 mcg/dL (normal: 20 to 80 mcg/dL)</p><p></p><p>A markedly elevated RBC PP is diagnostic in the rare case of late-onset erythropoietic protoporphyria (EPP) in the setting of an MDS-RS-SLD diagnosis, regardless of whether or not the patient exhibits photosensitivity associated with EPP [<a href="#rid77">77,84</a>]. The diagnostic evaluation of EPP is presented separately. (See <a class="local">'MDS/MPN variants'</a> above and  <a class="medical medical_review" href="/z/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria", section on 'Erythrocyte protoporphyrin'</a>.)</p><p class="headingAnchor" id="H974637647"><span class="h3">Copper levels</span><span class="headingEndMark"> — </span>Serum copper and ceruloplasmin levels are determined in individuals with suspected copper deficiency due to one of the conditions described above. In some cases, the serum zinc level may also be tested. (See <a class="local">'Copper deficiency'</a> above.)</p><p class="headingAnchor" id="H3662103772"><span class="h3">Molecular (genetic) testing</span><span class="headingEndMark"> — </span>In congenital sideroblastic anemias, genetic testing is the most definitive means of establishing the specific diagnosis and characterizing the pathogenic variant [<a href="#rid85">85</a>]. Genetic testing is performed by DNA sequence analysis using leukocytes from peripheral blood. </p><p>According to the patient's phenotype and its prevalence, single-gene Sanger sequencing can suffice. In other uncommon forms, given their clinical heterogeneity selection of genes to sequence is often difficult and becomes labor intensive. For these, next-generation sequencing tools (ie, custom targeting gene panels and/or whole exome sequencing [WES]) are time-efficient and have entered clinical practice [<a href="#rid86">86,87</a>]. (See  <a class="medical medical_review" href="/z/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications", section on 'Whole genome, exome, or gene panel'</a>.)</p><p>Accurate genetic diagnosis is important for management, such as for determining specific therapies or evaluations for other organ involvement in the syndromic conditions as well as genetic counseling and testing of first-degree relatives. (See <a class="local">'Congenital sideroblastic anemias'</a> above and <a class="local">'Genetic counseling and testing of first degree relatives'</a> below.)</p><p>The genes that are known to have pathogenic variants in the congenital sideroblastic anemias are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><em>ALAS2</em> – X-linked sideroblastic anemia (XLSA)</p><p class="bulletIndent1"><span class="glyph">●</span><em>SLC25A38</em>,<em> HSPA9</em>, <em>HSCB</em>, and<em> GLRX5</em> – Autosomal recessive nonsyndromic sideroblastic anemias</p><p class="bulletIndent1"><span class="glyph">●</span><em>ABCB7</em> – XLSA with ataxia (XLSA/A)</p><p class="bulletIndent1"><span class="glyph">●</span><em>NDUFB11</em> – X-linked sideroblastic anemia with variable syndromic features such as short stature, developmental delay, or myopathy</p><p class="bulletIndent1"><span class="glyph">●</span><em>TRNT1</em> – Sideroblastic anemia with immunodeficiency, periodic fevers, and developmental delay (SIFD)</p><p class="bulletIndent1"><span class="glyph">●</span><em>PUS1</em>, <em>YARS2</em>, <em>NDUFB11</em>,<em> MT-ATP6</em>, <em>LARS2, IARS2, </em>and <em>SARS2</em> – Myopathy, acidosis, and sideroblastic anemia (MLASA) and MLASA variants</p><p class="bulletIndent1"><span class="glyph">●</span><em>SLC19A2</em> – Thiamine-responsive megaloblastic anemia (TRMA)</p><p class="bulletIndent1"><span class="glyph">●</span><em>FECH</em> – Erythropoietic protoporphyria (EPP)</p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial DNA deletions and rearrangements – Pearson marrow-pancreas syndrome</p><p></p><p>In the MDS disorders with ring sideroblasts, acquired mutations in two genes that tend to confer a favorable prognosis are very common (see <a class="local">'MDS/MPN variants'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><em>SF3B1</em> – All three MDS/MPN disorders with ring sideroblasts</p><p class="bulletIndent1"><span class="glyph">●</span><em>JAK2 </em>V617F mutation – MPN with ring sideroblasts and thrombocytosis</p><p></p><p>Moreover, combining next-generation DNA sequencing with conventional sequencing methodology has allowed identification of spliceosome mutations in almost all MDS patients with ring sideroblasts [<a href="#rid88">88</a>].</p><p>Molecular analysis of the above-listed genes is available in various commercial or academic laboratories that are listed on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=7123" target="_blank">Genetic Testing Registry</a> website. Some may be available in certain research laboratories.</p><p class="headingAnchor" id="H2099056387"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of sideroblastic anemia includes other inherited and acquired anemias: the common microcytic anemias, several that are associated with neurologic findings, and other causes of abnormal red blood cell (RBC) inclusions that resemble Pappenheimer bodies. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other microcytic anemias</strong> – The most common microcytic anemias worldwide are iron deficiency anemia, thalassemia, and anemia of chronic disease/anemia of inflammation (ACD/AI). These would always first be excluded by assessing clinical findings and appropriate laboratory studies documenting (or excluding) these conditions before considering the microcytic sideroblastic anemias and performing bone marrow examination  (<a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/4432.html" rel="external">"Microcytosis/Microcytic anemia", section on 'Causes of microcytosis'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Megaloblastic anemias</strong> – Megaloblastic anemias are anemias in which DNA synthesis is impaired in developing RBC precursors, leading to anemia with an inappropriately low reticulocyte count, macrocytosis and multilobed neutrophils in the peripheral blood, and megaloblastic changes in the bone marrow (see  <a class="medical medical_review" href="/z/d/html/4434.html" rel="external">"Evaluation of bone marrow aspirate smears", section on 'Megaloblastic changes'</a>). Common causes include deficiency of vitamin B12 or folate, and certain medications. Like sideroblastic anemias, megaloblastic anemias present with anemia, low reticulocyte count, and sometimes neurologic findings, which may be quite variable. Unlike sideroblastic anemia, megaloblastic anemia is associated with megaloblastic changes rather than ring sideroblasts in the bone marrow, although ferritin sideroblasts (sideroblasts in which the granules are cytosolic, non-mitochondrial ferritin aggregates and do not encircle the nucleus) may be seen. If vitamin B12 or folate deficiency is responsible, laboratory testing in megaloblastic anemia shows the deficiency, whereas in sideroblastic anemia, deficiency of copper may be found. The drugs implicated in megaloblastic anemia differ from those implicated in sideroblastic anemia. (See  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a> and  <a class="medical medical_review" href="/z/d/html/7166.html" rel="external">"Macrocytosis/Macrocytic anemia", section on 'Drug-induced macrocytosis'</a> and <a class="local">'Medications'</a> above and  <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">"Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wilson disease</strong> – Wilson disease results from mutations in the <em>ATP7B</em> gene, which encodes an ATPase in hepatic cells responsible for copper transport. Like sideroblastic anemia, Wilson disease may be associated with anemia and neurologic findings. Unlike sideroblastic anemia, in Wilson disease, the anemia is due to hemolysis and the neurologic features are usually associated with the presence of Kayser-Fleischer rings. Like in sideroblastic anemia due to copper deficiency, in Wilson disease, the serum copper and ceruloplasmin levels are often low, but urinary copper excretion is high and diagnostic of the disease. (See  <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lead poisoning</strong> – Lead poisoning is often listed in textbooks as a cause of sideroblastic anemia. It is the author's experience, however, that lead poisoning is not associated with sideroblastic changes [<a href="#rid84">84</a>]. Like sideroblastic anemia, lead poisoning can cause anemia, a low reticulocyte count, and neurologic changes. Like sideroblastic anemia, lead poisoning is associated with disordered heme synthesis. Unlike sideroblastic anemia, lead poisoning typically produces heavy basophilic stippling rather than Pappenheimer bodies in RBCs or ring sideroblasts. Unlike sideroblastic anemia, lead poisoning is associated with elevated blood lead levels. (See  <a class="medical medical_review" href="/z/d/html/6491.html" rel="external">"Childhood lead poisoning: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2773.html" rel="external">"Lead exposure, toxicity, and poisoning in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other RBC inclusions</strong> – Basophilic stippling and other RBC inclusions may be confused with Pappenheimer bodies. Like sideroblastic anemias, these inclusions may be seen in the setting of various anemias. Unlike sideroblastic anemia, these inclusions are not iron-positive or associated with ring sideroblasts in the bone marrow. (See  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Red cell inclusions and other changes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta thalassemia</strong> – A 2017 report described a series of individuals with beta thalassemia whose definitive diagnosis was delayed, in whom bone marrow examinations documented ring sideroblasts [<a href="#rid89">89</a>]. Thus, in individuals with ring sideroblasts who lack congenital sideroblastic anemia mutations or causes of acquired sideroblastic anemia, beta thalassemia should be considered in the differential diagnosis. (See  <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)"</a>.)</p><p></p><p class="headingAnchor" id="H496543769"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3503913894"><span class="h2">Management overview</span><span class="headingEndMark"> — </span>Management of sideroblastic anemias depends on the severity of the anemia, whether reversible abnormalities are present, and whether the sideroblastic anemia is responsive to a specific agent.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsyndromic congenital sideroblastic anemias</strong> – For patients with nonsyndromic forms of congenital sideroblastic anemia, the treatment program must be aimed at prevention of organ damage from the associated iron overload, as well as control of the symptoms of anemia, to improve outcomes and reach close to normal survival. (See <a class="local">'Treatments for anemia'</a> below and <a class="local">'Iron overload'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">Vitamin B6</a> (pyridoxine) supplements are often effective in X-linked sideroblastic anemia (XLSA). (See <a class="local">'Vitamins'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">Luspatercept</a>, an erythroid maturation agent, may be useful in congenital sideroblastic anemias with prominent ineffective erythropoiesis. (See <a class="local">'Treatments for anemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic sideroblastic anemias</strong> – In most syndromic forms of congenital sideroblastic anemia, the clinical course is largely dominated by the nonhematologic features and their care. <a class="drug drug_general" data-topicid="9988" href="/z/d/drug information/9988.html" rel="external">Thiamine</a> is used to treat thiamine-responsive megaloblastic anemia (TRMA). (See <a class="local">'Vitamins'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reversible sideroblastic anemias</strong> – In copper deficiency, the hematologic abnormalities are promptly corrected by copper replacement. In drug-induced sideroblastic anemia, the anemia and associated morphologic abnormalities (siderocytes in the peripheral blood, ring sideroblasts in the bone marrow) are reversible and disappear upon drug withdrawal. For <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> (INH), the anemia can also be reversed by administering large doses of <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> (up to 200 mg/day orally) while continuing the INH, if needed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS </strong>– Management of myelodysplastic syndrome (MDS) is summarized below and discussed in more detail separately. (See <a class="local">'Treatments for anemia'</a> below and <a class="local">'Iron overload'</a> below and  <a class="medical medical_review" href="/z/d/html/16122.html" rel="external">"Overview of the treatment of myelodysplastic syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="headingAnchor" id="H4117075163"><span class="h2">Additional post-diagnosis testing</span><span class="headingEndMark"> — </span>For patients with congenital and acquired clonal sideroblastic anemia, the following laboratory studies are appropriate:</p><p class="bulletIndent1"><span class="glyph">●</span>Iron studies (serum transferrin saturation, ferritin), to determine the degree of iron overload, which will in turn guide the need for phlebotomy or iron chelation, and subsequent monitoring. For those with laboratory evidence of iron overload, the degree of iron deposition in tissues is best assessed using magnetic resonance imaging (MRI; using the T2* method) or by obtaining a liver biopsy, as serum ferritin values afford only a rough indication of the iron burden present [<a href="#rid90">90</a>]. The liver biopsy may also provide additional prognostic information through demonstration of any liver damage and/or cirrhosis. (See  <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte folate level (also called RBC folate), to identify a deficiency occasionally associated with ineffective erythropoiesis. This may be seen mainly in patients with XLSA or an autosomal recessive congenital sideroblastic anemia (ARCSA) and severe anemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma copper and ceruloplasmin levels, mainly in the clonal sideroblastic anemias to exclude copper deficiency, particularly if neutropenia or neurologic deficits are present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing is advised in all irreversible sideroblastic anemias  (<a class="graphic graphic_algorithm graphicRef135067" href="/z/d/graphic/135067.html" rel="external">algorithm 1</a>). A gene (or genes) is selected for analysis that is consistent with the patient's phenotype as discussed previously (See <a class="local">'Congenital sideroblastic anemias'</a> above and <a class="local">'MDS/MPN variants'</a> above.)</p><p></p><p class="headingAnchor" id="H91744951"><span class="h2">Treatments for anemia</span><span class="headingEndMark"> — </span>Treatment of anemia depends on its severity and associated symptoms. The goal should be to obtain a safe hemoglobin level and reduce symptoms, not to normalize the hemoglobin level.</p><p class="headingAnchor" id="H3088488552"><span class="h3">Transfusions</span><span class="headingEndMark"> — </span>For symptomatic anemic individuals, periodic transfusions are necessary to relieve symptoms, and, for children, to allow normal growth and development. Transfusion of red blood cells (RBCs) should be kept to a minimum as the iron contained in the transfused RBCs accelerates the degree of iron overload that is often already present. (See <a class="local">'Iron overload'</a> below.)</p><p class="headingAnchor" id="H1965996298"><span class="h3">Vitamins</span><span class="headingEndMark"> — </span>In specific disorders, the anemia may be responsive to a vitamin supplementation:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">Vitamin B6</a> (pyridoxine) is used in XLSA and drug-induced sideroblastic anemia from <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>XLSA may respond to <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> (pyridoxine) supplements in up to two-thirds of cases; hemoglobin concentrations return to normal in about one-third of the responders. The morphologic red cell abnormalities improve variably, but very rarely completely disappear [<a href="#rid77">77,91</a>]. It is prudent in all patients with congenital microcytic/hypochromic sideroblastic anemias to give a therapeutic trial of vitamin B6 for three months or until a specific genetic diagnosis other than XLSA is established. In XLSA, oral doses of vitamin B6 of 50 to 100 mg/day (over and above the estimated adult daily requirement of 1.5 to 2 mg/day) are sufficient for a maximal response; in one case, only 2 to 4 mg/day were found to be effective [<a href="#rid92">92</a>]. In responders, maintenance treatment with vitamin B6 is necessary, as relapse follows within several months after discontinuing treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In isoniazid-induced sideroblastic anemia, the <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> dosing is similar, but the <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> should be discontinued if possible (with substitution of another agent). If this is not advisable, vitamin B6 can be administered while continuing the isoniazid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9988" href="/z/d/drug information/9988.html" rel="external">Thiamine</a> is used to treat TRMA. In addition to clinical improvement of the anemia, the other clinical features (diabetes mellitus and deafness) may respond to thiamine to a lesser extent. Supraphysiologic oral doses of thiamine (ie, 25 to 75 mg/day) are necessary for an effect, but during puberty, supplements seem to become ineffective [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a report of a single patient with the syndromic form of congenital sideroblastic anemia and mitochondrial myopathy, treatment with coenzyme Q10 at an oral dose of 400 mg/day was associated with a dramatic decrease in red cell transfusion requirement and improvement in muscle strength [<a href="#rid94">94</a>]. (See  <a class="medical medical_review" href="/z/d/html/5149.html" rel="external">"Mitochondrial disorders: Treatment", section on 'Specific supplements'</a>.)</p><p></p><p class="headingAnchor" id="H689876249"><span class="h3">Luspatercept for congenital sideroblastic anemias with ineffective erythropoiesis</span><span class="headingEndMark"> — </span>A case report described use of <a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">luspatercept</a> to treat an adult with X-linked sideroblastic anemia due to a germline pathogenic variant in <em>ALAS2</em>; the patient had increasing anemia-related symptoms and a doubling in transfusion requirements (from 10 units per year to &gt;21 units per year) [<a href="#rid95">95</a>]. After six months of treatment, symptoms improved dramatically and baseline hemoglobin level increased from 7 g/dL to 9 g/dL, without significant adverse effects.</p><p>Given this case experience and observations that <a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">luspatercept</a> is effective in transfusion-dependent beta-thalassemia and MDS variants with ring sideroblasts, luspatercept is likely of value in congenital sideroblastic anemias associated with ineffective erythropoiesis, including XLSA, <em>SLC25A38</em> anemia, and SIFD [<a href="#rid96">96</a>]. As with MDS variants, its use is individualized. (See <a class="local">'Maturation promotors (luspatercept)'</a> below.) </p><p class="headingAnchor" id="H2163959803"><span class="h3">Anti-TNF agents for SIFD</span><span class="headingEndMark"> — </span>In a preliminary report of four individuals with sideroblastic anemia with immunodeficiency, periodic fevers, and developmental delay (SIFD), anti-tumor necrosis factor (TNF) therapy with <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> was effective in suppressing fevers, decreasing the need for transfusions, and improving laboratory markers of inflammation [<a href="#rid97">97</a>]. Although data are extremely limited, we would use this approach in severely affected individuals, initiating it early in life. The rationale for this approach is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (TRNT1 mutation)'</a> and  <a class="medical medical_review" href="/z/d/html/122509.html" rel="external">"Autoinflammatory diseases mediated by miscellaneous mechanisms", section on 'SIFD syndrome'</a>.)</p><p class="headingAnchor" id="H3120562648"><span class="h3">Agents for MDS/MPN variants</span><span class="headingEndMark"> — </span>For management of symptomatic anemia of the MDS/myeloproliferative neoplasm (MPN) variants with ring sideroblasts, guidelines for treatment of low-risk MDS would apply [<a href="#rid98">98</a>]. Agents used over the years, namely erythropoietins and/or granulocyte colony-stimulating factor (G-CSF), hypomethylating agents (<a class="drug drug_general" data-topicid="8797" href="/z/d/drug information/8797.html" rel="external">azacitidine</a>, <a class="drug drug_general" data-topicid="8855" href="/z/d/drug information/8855.html" rel="external">decitabine</a>), immunosuppressive therapy (antithymocyte globulin [ATG]), and imetelstat, are options for averting RBC transfusions with at best 50 percent response rates [<a href="#rid99">99,100</a>]. These therapies are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/16122.html" rel="external">"Overview of the treatment of myelodysplastic syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)"</a>.)</p><p>Newer options include <a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">luspatercept</a>, which promotes erythroid maturation, and splicing modulators, which remain investigational. (See <a class="local">'Maturation promotors (luspatercept)'</a> below and <a class="local">'Splicing modulators'</a> below.)</p><p class="headingAnchor" id="H1955434847"><span class="h4">Maturation promotors (luspatercept)</span><span class="headingEndMark"> — </span>In the randomized, double-blind MEDALIST trial, <a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">luspatercept</a>, a first-in-class erythroid maturation agent that promotes late-stage erythropoiesis, significantly reduced the need for RBC transfusions and led to hematologic improvement in patients with lower-risk MDS and ring sideroblasts who were transfusion-dependent [<a href="#rid101">101</a>].</p><p>Therapy was well-tolerated with rare drug discontinuation due to adverse effects. These results have generated considerable enthusiasm for use of <a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">luspatercept</a> in patients with the MDS/MPN variants with ring sideroblasts unresponsive to erythropoietin [<a href="#rid102">102</a>]. The decision to use luspatercept initially or after a trial of an erythropoiesis-stimulating agent is individualized.</p><p><a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">Luspatercept</a> was approved by the US Food and Drug Administration (FDA) for this indication in April 2020 [<a href="#rid103">103</a>]. Follow-up data indicate sustained benefits of its use [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H1014418245"><span class="h4">Splicing modulators</span><span class="headingEndMark"> — </span>The use of splicing inhibitors or modulators to target the spliceosome harboring the mutations in MDS is another unique approach being investigated [<a href="#rid105">105</a>]. These therapies are not clinically available.</p><p class="headingAnchor" id="H3512925841"><span class="h3">Role of hematopoietic stem cell transplant</span><span class="headingEndMark"> — </span>Definitive cure for some nonsyndromic forms of inherited sideroblastic anemia has been documented in an increasing number of patients treated with allogeneic hematopoietic stem cell transplantation (HSCT), although the number of transplanted patients remains small [<a href="#rid1">1,106-114</a>]. For individuals in whom the genetic cause was identified, 20 patients had <em>SLC25A38</em> anemia and one had XLSA. Among 32 patients who were transplanted, approximately 84 percent had apparent cure. However, out of five patients with SIFD who were transplanted, only two survived [<a href="#rid115">115</a>]. HSCT can thus be considered in young, transfusion-dependent patients with appropriate donors before developing sequelae of chronic transfusions. Existing iron overload should be controlled prior to transplantation for optimal outcomes.</p><p>With effective HSCT using gene therapy in curing beta-thalassemia, a similar commitment marshaled for selected, transfusion-dependent patients with genetic sideroblastic anemia could also become a reality. (See  <a class="medical medical_review" href="/z/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Inherited single gene disorders'</a> and  <a class="medical medical_review" href="/z/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Gene therapy and other stem cell modifications'</a>.)</p><p>HSCT is rarely used for MDS/MPN variants with ring sideroblasts, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Intensive therapies'</a>.)</p><p class="headingAnchor" id="H1333799421"><span class="h2">Iron overload</span><span class="headingEndMark"> — </span>Many patients with sideroblastic anemia develop iron overload as a result of the ineffective erythropoiesis and/or transfusions [<a href="#rid6">6,116,117</a>]. Mild to moderate degrees of hepatosplenomegaly are common, but liver function is usually normal or only mildly disturbed at presentation. Liver biopsy reveals a pattern of iron deposition that is indistinguishable from that of hereditary hemochromatosis  (<a class="graphic graphic_picture graphicRef60882" href="/z/d/graphic/60882.html" rel="external">picture 9</a>). In XLSA patients, well-established but asymptomatic micronodular cirrhosis may be discovered by the third or fourth decade, which does not correlate with severity of the anemia  (<a class="graphic graphic_picture graphicRef62989" href="/z/d/graphic/62989.html" rel="external">picture 10</a>) [<a href="#rid116">116,118,119</a>]. Hepatocellular carcinoma developed in two reported cases with XLSA [<a href="#rid120">120,121</a>]. </p><p>Cardiac complications (arrhythmia, heart failure) occur with advanced iron overload in the heart  (<a class="graphic graphic_picture graphicRef81850" href="/z/d/graphic/81850.html" rel="external">picture 11</a>) and are the usual cause of a fatal outcome.</p><p>Control of iron overload in sideroblastic anemias is an important aspect of management. Even patients with several common forms of sideroblastic anemia who do not receive transfusions develop systemic iron overload over time because ineffective erythropoiesis leads to increased iron absorption. Necessary chronic transfusions predictably add to the body iron burden and its consequences. Removal of excess iron has also improved the anemia in some cases. Ideally, development of any iron overload in the sideroblastic anemias should be prevented prospectively, although usually not achieved. (See  <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">"Regulation of iron balance"</a> and  <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Ineffective erythropoiesis'</a>.)</p><p>Severity of iron overload is best assessed by T2* MRI or liver biopsy (see <a class="local">'Additional post-diagnosis testing'</a> above). An iron depletion program is initiated if the serum ferritin exceeds 500 to 1000 ng/mL, or after transfusion of 20 to 25 units of RBCs (in adults), or if liver iron content is over 3 mg iron/g dry weight. Iron depletion is accomplished in one of two ways: therapeutic phlebotomy or iron chelation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic phlebotomy</strong> – Iron depletion is best performed by phlebotomy when the anemia is mild or moderate (ie, hemoglobin &gt;9 g/dL) or when a patient with XLSA has had a sufficient response to <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a>, provided there are no contraindications to therapeutic phlebotomy such as congestive heart failure [<a href="#rid122">122,123</a>]. Half-unit phlebotomies may be carried out initially in order for the anemic patient to adjust to this regimen. Once the serum ferritin level has been reduced sufficiently, maintenance phlebotomies are continued on a regular basis for life, to prevent re-accumulation of iron. (See  <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a> and  <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis", section on 'Phlebotomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron chelation therapy</strong> – In patients who have more severe anemia, and in those who require regular RBC transfusions and thus cannot undergo phlebotomy, iron chelation is used. The available agents in the United States are <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> (Desferal) for parenteral administration and <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">deferasirox</a> (Exjade) as the oral preparation. Details of specific chelating agents are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects", section on 'Available chelating agents'</a>.)</p><p></p><p class="bulletIndent1">For the congenital sideroblastic anemias, owing to their uncommon occurrence, a large patient series describing results of iron chelation is not available. However, clinical experience over the past 50 years in this young population has demonstrated that, much like extensively shown in thalassemia, effective iron chelation therapy provides for normal growth and development as well as significantly reduces or averts morbidity and mortality due to iron overload. The first detailed guidelines on monitoring and management of iron overload in hemoglobinopathies and rare anemias were published in 2021 from the British Society for Haematology [<a href="#rid124">124</a>]. These guidelines for the first time interpret the available evidence on chelation as best applied to each type of anemia. </p><p></p><p class="bulletIndent1">In the clonal sideroblastic anemias (MDS/MPN variants), in which iron overload often develops well before transfusion dependence but is greatly accentuated by eventual chronic transfusions, iron chelation has provided favorable supportive therapy for many patients, despite some individuals debating its clinical utility [<a href="#rid125">125</a>]. In this group of older patients, we use an individualized approach for managing iron overload by also considering the patient's clinical status and life expectancy. </p><p></p><p class="bulletIndent1">The benefit of iron chelation in reducing morbidities associated with iron overload in transfusion-dependent, lower-risk MDS was demonstrated in the first prospective, placebo-controlled trial, TELESTO. In TELESTO, 225 individuals with low-risk MDS and transfusional iron overload were assigned to receive <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">deferasirox</a> or placebo for at least one year [<a href="#rid126">126</a>]. Patients treated with deferasirox had longer event-free survival (no cardiac or liver dysfunction or transformation to acute myeloid leukemia [AML]) of 3.9 years versus 3.0 years with placebo (hazard ratio [HR] 0.64 [95% CI 0.42-0.96]). Median overall survival in the deferasirox group showed a trend towards improvement (5.2 versus 4.1 years; HR 0.83 [95% CI 0.54-1.28]). Serious adverse events were somewhat greater with deferasirox (54 versus 50 percent). The trial size was hampered by slow enrollment. </p><p></p><p>An investigational approach to managing the iron overload due to ineffective erythropoiesis involves use of an antibody to the iron-regulatory erythrokine erythroferrone (ERFE), which mediates the increased iron absorption via suppression of hepcidin production by the liver. Preclinical studies in a murine model of beta thalassemia have shown that an anti-ERFE monoclonal antibody increased hemoglobin levels and decreased serum iron levels and systemic iron overload [<a href="#rid127">127</a>].</p><p class="headingAnchor" id="H3571748891"><span class="h2">Avoidance of splenectomy</span><span class="headingEndMark"> — </span>There has been a temptation to perform splenectomy in patients with severe anemia and a significant degree of splenomegaly with suspected splenic sequestration of RBCs. However, this procedure is almost invariably complicated by postoperative thromboembolic events and often a fatal outcome [<a href="#rid128">128-131</a>]. Factors other than persistent thrombocytosis appear to play a role; control of the platelet count and anticoagulant therapy usually are not effective. Thus, splenectomy is considered to be <strong>contraindicated</strong> in the congenital sideroblastic anemias save for a case of clinical urgency such as traumatic splenic rupture or otherwise untreatable splenic abscess. We also suggest avoiding splenectomy in individuals with the long-lived myelodysplastic syndrome variants MDS-RS-SLD (previously called RARS) and MDS/MPN-RS-T (previously called RARS-T). (See <a class="local">'MDS/MPN variants'</a> above.)</p><p class="headingAnchor" id="H391315375"><span class="h2">Genetic counseling and testing of first degree relatives</span><span class="headingEndMark"> — </span>For patients with inherited sideroblastic anemia, we educate the patient or family about the disease and relevant inheritance pattern. We also obtain a full family history and a complete blood count (CBC) on each parent and sibling. When the genetic defect has been identified in the index case, it can be easily confirmed in any affected family members by genetic (DNA) testing.</p><p>In the X-linked anemias, we advise all young women who are candidates for having a pathogenic variant to be tested for carrier status. Testing of the parents can be used to determine whether the defect in the proband has been transmitted or is a de novo mutation.</p><p>In autosomal recessive forms, the genetic status of the parents of an affected and genetically identified offspring can be confirmed and used for counseling regarding future pregnancies, including consideration of prenatal testing or preimplantation genetic testing (PGT). In one family, preimplantation diagnosis was used and resulted in unaffected twin offspring [<a href="#rid132">132</a>]. (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.)</p><p class="headingAnchor" id="H2411727494"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111043.html" rel="external">"Society guideline links: Anemia in adults"</a>.)</p><p class="headingAnchor" id="H3563029"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inherited</strong> – Inherited sideroblastic anemias include nonsyndromic and syndromic disorders  (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>). These can also be categorized by red blood cell (RBC) size (microcytic or normocytic/macrocytic)  (<a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>) and by inheritance pattern (X-linked, autosomal, or mitochondrial). X-linked sideroblastic anemia (XLSA) is the most common congenital sideroblastic anemia. Although it is X-linked, up to one-third of cases occur in females. (See <a class="local">'Congenital sideroblastic anemias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired</strong> – Acquired sideroblastic anemias include clonal bone marrow disorders that are classified within the rubric of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), as well as reversible conditions attributed to copper deficiency, certain medications, or excessive alcohol use. (See <a class="local">'Acquired sideroblastic anemias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Sideroblastic anemia is often considered in the differential diagnosis of unexplained anemia after more common causes have been excluded. The diagnosis of <strong>all</strong> sideroblastic anemias is made by identifying the telltale ring sideroblasts on the bone marrow aspirate smear. Distinction among the specific forms of sideroblastic anemia involves evaluation of clinical features and laboratory testing, often followed by genetic testing  (<a class="graphic graphic_algorithm graphicRef135067" href="/z/d/graphic/135067.html" rel="external">algorithm 1</a>). (See <a class="local">'Overview of diagnostic issues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children and young adults</strong> – In a child or young adult, congenital sideroblastic anemia may be suspected from known family history, clinical features that suggest a syndromic condition, or lack of another diagnosis. The spectrum of associated clinical features in some syndromic congenital sideroblastic anemias is wide and may not fully manifest at presentation; thus, some of the inherited forms may not be correctly diagnosed until later in life. (See <a class="local">'Child/young adult (&lt;20 years) evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adults</strong> – In adults, acquired sideroblastic anemia is more common than inherited, although there are often delays in diagnosis of congenital types until adulthood. The two typical presentations are a clinical history consistent with a reversible cause and a bone marrow aspirate showing ring sideroblasts. Almost all of the acquired sideroblastic anemias produce normocytic or macrocytic RBCs. For individuals with suspected MDS/MPN variants, other causes of sideroblastic anemia must be excluded, such as copper deficiency, medications, and XLSA in females. (See <a class="local">'Adult evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – Testing involves review of the complete blood count (CBC), peripheral blood smear, and bone marrow aspirate smear, including iron stain. Patients may require additional testing such as iron studies. Molecular/genetic testing is appropriate when the bone marrow shows ring sideroblasts or when a congenital sideroblastic anemia or MDS/MPN variant is suspected. (See <a class="local">'Laboratory and bone marrow findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential</strong> – The differential diagnosis includes inherited and acquired anemias, several of which have neurologic findings (megaloblastic anemias, Wilson disease, lead poisoning), and causes of RBC inclusions that resemble Pappenheimer bodies. Iron deficiency and thalassemia should be excluded in individuals with microcytosis and/or poikilocytosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management depends on the severity of the anemia, whether reversible abnormalities are present, and whether the anemia is responsive to a specific agent such as <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a>. Management of anemia and iron overload are critical. Splenectomy is avoided. Genetic counseling and testing of first-degree relatives is appropriate with inherited forms. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Luspatercept</strong> <strong>for selected individuals</strong> – <a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">Luspatercept</a> is an erythroid maturation agent; it is an option for individuals with MDS/MPN variants with ring sideroblasts who have transfusion-dependent anemia. The decision to use luspatercept initially or after a trial of an erythropoiesis-stimulating agent is individualized. A case report indicates that luspatercept may be effective in the common congenital sideroblastic anemias; this is also an individualized decision. (See <a class="local">'Treatments for anemia'</a> above and  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="headingAnchor" id="H1073854719"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Heeney MM, Berhe S, Campagna DR, et al. SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. Hum Mutat 2021; 42:1367.</a></li><li><a class="nounderline abstract_t">Dobyns WB, Filauro A, Tomson BN, et al. Inheritance of most X-linked traits is not dominant or recessive, just X-linked. Am J Med Genet A 2004; 129A:136.</a></li><li><a class="nounderline abstract_t">Aivado M, Gattermann N, Rong A, et al. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells Mol Dis 2006; 37:40.</a></li><li><a class="nounderline abstract_t">Sankaran VG, Ulirsch JC, Tchaikovskii V, et al. X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. J Clin Invest 2015; 125:1665.</a></li><li><a class="nounderline abstract_t">Thomas B, Visanica S, Poussing S, et al. Is this really thalassemia? Am J Hematol 2023; 98:1814.</a></li><li><a class="nounderline abstract_t">Simpson SJ, Lim MY, George TI, Rets A. 36-year-old male with X-linked congenital sideroblastic anemia presenting as chronic microcytic anemia with iron overload. Int J Lab Hematol 2022; 44:69.</a></li><li><a class="nounderline abstract_t">Fairbanks VF, Dickson ER, Thompson ME. Hereditary sideroblastic anemia. Hosp Pract (Off Ed) 1991; 26 Suppl 3:53.</a></li><li><a class="nounderline abstract_t">Bottomley SS, Wise PD, Wasson EG, et al. X-linked sideroblastic anemia in ten female probands due to ALAS2 mutations and skewed X chromosome inactivation. Am J Hum Genet 1998; 63:A352.</a></li><li><a class="nounderline abstract_t">Garçon L, Kannengiesser C. A double red cells population in a woman with a microcytic anemia. Blood 2014; 123:808.</a></li><li><a class="nounderline abstract_t">Cortesão E, Vidan J, Pereira J, et al. Onset of X-linked sideroblastic anemia in the fourth decade. Haematologica 2004; 89:1261.</a></li><li><a class="nounderline abstract_t">Rose C, Callebaut I, Pascal L, et al. Lethal ALAS2 mutation in males X-linked sideroblastic anaemia. Br J Haematol 2016; 178:648.</a></li><li><a class="nounderline abstract_t">Cotter PD, May A, Li L, et al. Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood 1999; 93:1757.</a></li><li><a class="nounderline abstract_t">Bekri S, Kispal G, Lange H, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood 2000; 96:3256.</a></li><li><a class="nounderline abstract_t">Maguire A, Hellier K, Hammans S, May A. X-linked cerebellar ataxia and sideroblastic anaemia associated with a missense mutation in the ABC7 gene predicting V411L. Br J Haematol 2001; 115:910.</a></li><li><a class="nounderline abstract_t">Pagon RA, Bird TD, Detter JC, Pierce I. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet 1985; 22:267.</a></li><li><a class="nounderline abstract_t">Allikmets R, Raskind WH, Hutchinson A, et al. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 1999; 8:743.</a></li><li><a class="nounderline abstract_t">Lichtenstein DA, Crispin AW, Sendamarai AK, et al. A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood 2016; 128:1913.</a></li><li><a class="nounderline abstract_t">Torraco A, Bianchi M, Verrigni D, et al. A novel mutation in NDUFB11 unveils a new clinical phenotype associated with lactic acidosis and sideroblastic anemia. Clin Genet 2017; 91:441.</a></li><li><a class="nounderline abstract_t">Odom J, Amin H, Gijavanekar C, et al. A phenotypic expansion of TRNT1 associated sideroblastic anemia with immunodeficiency, fevers, and developmental delay. Am J Med Genet A 2022; 188:259.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li><a class="nounderline abstract_t">Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008; 93:34.</a></li><li><a class="nounderline abstract_t">Broséus J, Alpermann T, Wulfert M, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27:1826.</a></li><li><a class="nounderline abstract_t">Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 2015; 126:233.</a></li><li><a class="nounderline abstract_t">Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 1990; 74:45.</a></li><li><a class="nounderline abstract_t">Germing U, Gattermann N, Aivado M, et al. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 2000; 108:724.</a></li><li><a class="nounderline abstract_t">Halfdanarson TR, Kumar N, Hogan WJ, Murray JA. Copper deficiency in celiac disease. J Clin Gastroenterol 2009; 43:162.</a></li><li><a class="nounderline abstract_t">Prodan CI, Bottomley SS, Vincent AS, et al. Copper deficiency after gastric surgery: a reason for caution. Am J Med Sci 2009; 337:256.</a></li><li><a class="nounderline abstract_t">Sonu RJ, Rashidi HH. Concurrent copper and iron deficiency in a gastric bypass patient: a great mimicker of MDS. Blood 2015; 125:2582.</a></li><li><a class="nounderline abstract_t">von Drygalski A, Andris DA. Anemia after bariatric surgery: more than just iron deficiency. Nutr Clin Pract 2009; 24:217.</a></li><li><a class="nounderline abstract_t">Choi EH, Strum W. Hypocupremia-related myeloneuropathy following gastrojejunal bypass surgery. Ann Nutr Metab 2010; 57:190.</a></li><li><a class="nounderline abstract_t">Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood 2002; 100:1493.</a></li><li><a class="nounderline abstract_t">Saxena K, Vu K, Nye HE. A 54-Year-Old Man With Pancytopenia. JAMA 2019; 321:895.</a></li><li><a class="nounderline abstract_t">Vilter RW, Bozian RC, Hess EV, et al. Manifestations of copper deficiency in a patient with systemic sclerosis on intravenous hyperalimentation. N Engl J Med 1974; 291:188.</a></li><li><a class="nounderline abstract_t">Takeuchi M, Tada A, Yoshimoto S, Takahashi K. [Anemia and neutropenia due to copper deficiency during long-term total parenteral nutrition]. Rinsho Ketsueki 1993; 34:171.</a></li><li><a class="nounderline abstract_t">Nagano T, Toyoda T, Tanabe H, et al. Clinical features of hematological disorders caused by copper deficiency during long-term enteral nutrition. Intern Med 2005; 44:554.</a></li><li><a class="nounderline abstract_t">Pirruccello E, Luu HS, Chen W. Haematogone hyperplasia in copper deficiency. Br J Haematol 2016; 173:335.</a></li><li><a class="nounderline abstract_t">Al-Bubseree B, Leach M, Jones R, Bain BJ. The hematological effects of copper deficiency. Am J Hematol 2020; 95:446.</a></li><li><a class="nounderline abstract_t">Fiske DN, McCoy HE 3rd, Kitchens CS. Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome. Am J Hematol 1994; 46:147.</a></li><li><a class="nounderline abstract_t">Irving JA, Mattman A, Lockitch G, et al. Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. CMAJ 2003; 169:129.</a></li><li><a class="nounderline abstract_t">Nations SP, Boyer PJ, Love LA, et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology 2008; 71:639.</a></li><li><a class="nounderline abstract_t">Hedera P, Peltier A, Fink JK, et al. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc. Neurotoxicology 2009; 30:996.</a></li><li><a class="nounderline abstract_t">Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990; 264:1441.</a></li><li><a class="nounderline abstract_t">Hassan HA, Netchvolodoff C, Raufman JP. Zinc-induced copper deficiency in a coin swallower. Am J Gastroenterol 2000; 95:2975.</a></li><li><a class="nounderline abstract_t">Pawa S, Khalifa AJ, Ehrinpreis MN, et al. Zinc toxicity from massive and prolonged coin ingestion in an adult. Am J Med Sci 2008; 336:430.</a></li><li><a class="nounderline abstract_t">Dolcourt BA, Paxton JH, Bora KM, Aaron CK. Pennies for Your Thoughts: A Case Series of Pancytopenia Due to Zinc-induced Copper Deficiency in the Same Patient. Clin Pract Cases Emerg Med 2019; 3:341.</a></li><li><a class="nounderline abstract_t">Francis Z, Book G, Litvin C, Kalivas B. The COVID-19 Pandemic and Zinc-Induced Copper Deficiency: An Important Link. Am J Med 2022; 135:e290.</a></li><li><a class="nounderline abstract_t">Perry AR, Pagliuca A, Fitzsimons EJ, et al. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol 1996; 64:69.</a></li><li><a class="nounderline abstract_t">Cousins RJ. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 1985; 65:238.</a></li><li><a class="nounderline abstract_t">Prodan CI, Holland NR, Wisdom PJ, et al. CNS demyelination associated with copper deficiency and hyperzincemia. Neurology 2002; 59:1453.</a></li><li><a class="nounderline abstract_t">Prodan CI, Holland NR, Wisdom PJ, Bottomley SS. Myelopathy due to copper deficiency. Neurology 2004; 62:1655.</a></li><li><a class="nounderline abstract_t">Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol 2005; 123:125.</a></li><li><a class="nounderline abstract_t">Rowin J, Lewis SL. Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation. J Neurol Neurosurg Psychiatry 2005; 76:750.</a></li><li><a class="nounderline abstract_t">Kumar N, Elliott MA, Hoyer JD, et al. "Myelodysplasia," myeloneuropathy, and copper deficiency. Mayo Clin Proc 2005; 80:943.</a></li><li><a class="nounderline abstract_t">Prodan CI, Bottomley SS, Holland NR, Lind SE. Relapsing hypocupraemic myelopathy requiring high-dose oral copper replacement. J Neurol Neurosurg Psychiatry 2006; 77:1092.</a></li><li><a class="nounderline abstract_t">Roberts PD, Hoffbrand AV, Mollin DL. Iron and folate metabolism in tuberculosis. Br Med J 1966; 2:198.</a></li><li><a class="nounderline abstract_t">Piso RJ, Kriz K, Desax MC. Severe isoniazid related sideroblastic anemia. Hematol Rep 2011; 3:e2.</a></li><li><a class="nounderline abstract_t">Rao S, Murali N, Permi VD, Shetty AK. Sideroblastic Anemia Associated With Isoniazid Prophylaxis in a Person Living With HIV. Am J Ther 2020; 27:e409.</a></li><li class="breakAll">Bottomley SS. Sideroblastic anaemia. In: Iron in Biochemistry and Medicine II, Jacobs A, Worwood M (Eds), Academic Press, London 1980. p.363.</li><li><a class="nounderline abstract_t">Haden HT. Pyridoxine-responsive sideroblastic anemia due to antituberculous drugs. Arch Intern Med 1967; 120:602.</a></li><li><a class="nounderline abstract_t">Hines JD, Love DS. Determination of serum and blood pyridoxal phosphate concentrations with purified rabbit skeletal muscle apophosphorylase b. J Lab Clin Med 1969; 73:343.</a></li><li><a class="nounderline abstract_t">Standal BR, Kao-Chen SM, Yang GY, Char DF. Early changes in pyridoxine status of patients receiving isoniazid therapy. Am J Clin Nutr 1974; 27:479.</a></li><li><a class="nounderline abstract_t">Beck EA, Ziegler G, Schmid R, Lüdin H. Reversible sideroblastic anemia caused by chloramphenicol. Acta Haematol 1967; 38:1.</a></li><li><a class="nounderline abstract_t">SCOTT JL, FINEGOLD SM, BELKIN GA, LAWRENCE JS. A CONTROLLED DOUBLE-BLIND STUDY OF THE HEMATOLOGIC TOXICITY OF CHLORAMPHENICOL. N Engl J Med 1965; 272:1137.</a></li><li><a class="nounderline abstract_t">Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294:93.</a></li><li><a class="nounderline abstract_t">Montpetit MC, Shammo JL, Loew J, et al. Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device. J Heart Lung Transplant 2004; 23:1119.</a></li><li><a class="nounderline abstract_t">Saini N, Jacobson JO, Jha S, et al. The perils of not digging deep enough--uncovering a rare cause of acquired anemia. Am J Hematol 2012; 87:413.</a></li><li><a class="nounderline abstract_t">Liapis K, Vrachiolias G, Spanoudakis E, Kotsianidis I. Vacuolation of early erythroblasts with ring sideroblasts: a clue to the diagnosis of linezolid toxicity. Br J Haematol 2020; 190:809.</a></li><li><a class="nounderline abstract_t">Vial T, Grignon M, Daumont M, et al. Sideroblastic anaemia during fusidic acid treatment. Eur J Haematol 2004; 72:358.</a></li><li><a class="nounderline abstract_t">Condamine L, Hermine O, Alvin P, et al. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. Br J Haematol 1993; 83:166.</a></li><li><a class="nounderline abstract_t">Kandola L, Swannell AJ, Hunter A. Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis. Ann Rheum Dis 1995; 54:529.</a></li><li><a class="nounderline abstract_t">Colucci G, Silzle T, Solenthaler M. Pyrazinamide-induced sideroblastic anemia. Am J Hematol 2012; 87:305.</a></li><li><a class="nounderline abstract_t">Savage D, Lindenbaum J. Anemia in alcoholics. Medicine (Baltimore) 1986; 65:322.</a></li><li><a class="nounderline abstract_t">Eichner ER, Hillman RS. The evolution of anemia in alcoholic patients. Am J Med 1971; 50:218.</a></li><li><a class="nounderline abstract_t">Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 2010; 54:273.</a></li><li><a class="nounderline abstract_t">Ducamp S, Kannengiesser C, Touati M, et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 2011; 32:590.</a></li><li><a class="nounderline abstract_t">Liu G, Guo S, Kang H, et al. Mutation spectrum in Chinese patients affected by congenital sideroblastic anemia and a search for a genotype-phenotype relationship. Haematologica 2013; 98:e158.</a></li><li class="breakAll">Bottomley SS, Fleming MD. Sideroblastic anemias. In: Wintrobe's Clinical Hematology, 14th ed, Greer JP, Rodgers GM, Glader B, et al (Eds), Wolters Kluwer, Philadelphia 2019. p.644.</li><li><a class="nounderline abstract_t">Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am 2014; 28:653.</a></li><li><a class="nounderline abstract_t">MOLLIN DL. SIDEROBLASTS AND SIDEROBLASTIC ANAEMIA. Br J Haematol 1965; 11:41.</a></li><li><a class="nounderline abstract_t">Bottomley SS. Sideroblastic anaemia. Clin Haematol 1982; 11:389.</a></li><li><a class="nounderline abstract_t">Lefèvre C, Bondu S, Le Goff S, et al. Dyserythropoiesis of myelodysplastic syndromes. Curr Opin Hematol 2017; 24:191.</a></li><li><a class="nounderline abstract_t">Falcon CP, Howard TH. An infant with Pearson syndrome: a rare cause of congenital sideroblastic anemia and bone marrow failure. Blood 2017; 129:2710.</a></li><li><a class="nounderline abstract_t">Li G, Hilliard LM. Morphologic features of normoblasts in a case of myopathy, lactic acidosis, and sideroblastic anemia. Blood 2017; 129:1057.</a></li><li><a class="nounderline abstract_t">Bottomley SS, Muller-Eberhard U. Pathophysiology of heme synthesis. Semin Hematol 1988; 25:282.</a></li><li><a class="nounderline abstract_t">Ducamp S, Fleming MD. The molecular genetics of sideroblastic anemia. Blood 2019; 133:59.</a></li><li><a class="nounderline abstract_t">Russo R, Marra R, Rosato BE, et al. Genetics and Genomics Approaches for Diagnosis and Research Into Hereditary Anemias. Front Physiol 2020; 11:613559.</a></li><li><a class="nounderline abstract_t">Steinberg-Shemer O, Tamary H. Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Congenital Anemias. Mol Diagn Ther 2020; 24:397.</a></li><li><a class="nounderline abstract_t">Janusz K, Del Rey M, Abáigar M, et al. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts. Leuk Res 2017; 56:82.</a></li><li><a class="nounderline abstract_t">Cattivelli K, Campagna DR, Schmitz-Abe K, et al. Ringed sideroblasts in β-thalassemia. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Wood JC. Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin North Am 2014; 28:747.</a></li><li><a class="nounderline abstract_t">Cotter PD, May A, Fitzsimons EJ, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest 1995; 96:2090.</a></li><li><a class="nounderline abstract_t">Cox TC, Bottomley SS, Wiley JS, et al. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med 1994; 330:675.</a></li><li><a class="nounderline abstract_t">Bergmann AK, Sahai I, Falcone JF, et al. Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J Pediatr 2009; 155:888.</a></li><li><a class="nounderline abstract_t">Bachmeyer C, Ferroir JP, Eymard B, et al. Coenzyme Q is effective on anemia in a patient with sideroblastic anemia and mitochondrial myopathy. Blood 2010; 116:3681.</a></li><li><a class="nounderline abstract_t">Van Dijck R, Goncalves Silva AM, Rijneveld AW. Luspatercept as Potential Treatment for Congenital Sideroblastic Anemia. N Engl J Med 2023; 388:1435.</a></li><li><a class="nounderline abstract_t">Sheth S, Taher AT, Coates TD, et al. Management of luspatercept therapy in patients with transfusion-dependent β-thalassaemia. Br J Haematol 2023; 201:824.</a></li><li><a class="nounderline abstract_t">Giannelou A, Wang H, Zhou Q, et al. Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors. Ann Rheum Dis 2018; 77:612.</a></li><li><a class="nounderline abstract_t">Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017; 15:60.</a></li><li><a class="nounderline abstract_t">Santini V. Treatment of low-risk myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2016; 2016:462.</a></li><li><a class="nounderline abstract_t">Giagounidis A. Current treatment algorithm for the management of lower-risk MDS. Hematology Am Soc Hematol Educ Program 2017; 2017:453.</a></li><li><a class="nounderline abstract_t">Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med 2020; 382:140.</a></li><li><a class="nounderline abstract_t">Komrokji RS. Luspatercept in Myelodysplastic Syndromes: Who and When? Hematol Oncol Clin North Am 2020; 34:393.</a></li><li class="breakAll">Luspatercept-aamt. United States prescribing information. Revised April 2020. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761136orig2lbl.pdf (Accessed on April 07, 2020).</li><li><a class="nounderline abstract_t">Zeidan AM, Platzbecker U, Garcia-Manero G, et al. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood 2022; 140:2170.</a></li><li><a class="nounderline abstract_t">Pellagatti A, Boultwood J. Splicing factor mutant myelodysplastic syndromes: Recent advances. Adv Biol Regul 2020; 75:100655.</a></li><li><a class="nounderline abstract_t">Urban C, Binder B, Hauer C, Lanzer G. Congenital sideroblastic anemia successfully treated by allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 10:373.</a></li><li><a class="nounderline abstract_t">González MI, Caballero D, Vázquez L, et al. Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. Br J Haematol 2000; 109:658.</a></li><li><a class="nounderline abstract_t">Ayas M, Al-Jefri A, Mustafa MM, et al. Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation. Br J Haematol 2001; 113:938.</a></li><li><a class="nounderline abstract_t">Medeiros BC, Kolhouse JF, Cagnoni PJ, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia. Bone Marrow Transplant 2003; 31:1053.</a></li><li><a class="nounderline abstract_t">Meo A, Ruggeri A, La Rosa MA, et al. Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation. Hemoglobin 2006; 30:131.</a></li><li><a class="nounderline abstract_t">Wiseman DH, May A, Jolles S, et al. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood 2013; 122:112.</a></li><li><a class="nounderline abstract_t">Kim MH, Shah S, Bottomley SS, Shah NC. Reduced-toxicity allogeneic hematopoietic stem cell transplantation in congenital sideroblastic anemia. Clin Case Rep 2018; 6:1841.</a></li><li><a class="nounderline abstract_t">Ma Z, Li D, Yang X, et al. Case report: An infant boy with X-linked sideroblastic anaemia successfully treated by umbilical cord blood haematopoietic stem cell transplantation. Front Genet 2022; 13:1009988.</a></li><li><a class="nounderline abstract_t">Shamsian BS, Jafari MR, Abolghasemi H, et al. Allogenic Hematopoietic Stem Cell Transplant in Iranian Patients With Congenital Sideroblastic Anemia: A Single-Center Experience. Exp Clin Transplant 2023; 21:70.</a></li><li><a class="nounderline abstract_t">Li Y, Deng M, Han T, et al. Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). J Clin Immunol 2023; 43:780.</a></li><li class="breakAll">Bottomley SS. Iron overload in sideroblastic and other non-thalassemic anemias. In: Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment, Barton JC, Edwards CQ (Eds), Cambridge University Press, Cambridge 2000. p.442.</li><li><a class="nounderline abstract_t">Tanno T, Miller JL. Iron Loading and Overloading due to Ineffective Erythropoiesis. Adv Hematol 2010; 2010:358283.</a></li><li><a class="nounderline abstract_t">Marcus RE. Iron overload in mild sideroblastic anaemia. Lancet 1983; 1:1276.</a></li><li><a class="nounderline abstract_t">Peto TE, Pippard MJ, Weatherall DJ. Iron overload in mild sideroblastic anaemias. Lancet 1983; 1:375.</a></li><li><a class="nounderline abstract_t">Barton JC, Lee PL. Disparate phenotypic expression of ALAS2 R452H (nt 1407 G --&gt; A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma. Blood Cells Mol Dis 2006; 36:342.</a></li><li><a class="nounderline abstract_t">Cuijpers ML, van Spronsen DJ, Muus P, et al. Need for early recognition and therapeutic guidelines of congenital sideroblastic anaemia. Int J Hematol 2011; 94:97.</a></li><li><a class="nounderline abstract_t">Bottomley SS. The spectrum and role of iron overload in sideroblastic anemia. Ann N Y Acad Sci 1988; 526:331.</a></li><li><a class="nounderline abstract_t">Hines JD. Effect of pyridoxine plus chronic phlebotomy on the function and morphology of bone marrow and liver in pyridoxine-responsive sideroblastic anemia. Semin Hematol 1976; 13:133.</a></li><li><a class="nounderline abstract_t">Shah FT, Porter JB, Sadasivam N, et al. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. Br J Haematol 2022; 196:336.</a></li><li><a class="nounderline abstract_t">Gattermann N. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation? Hematol Oncol Clin North Am 2020; 34:465.</a></li><li><a class="nounderline abstract_t">Angelucci E, Li J, Greenberg P, et al. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Ann Intern Med 2020; 172:513.</a></li><li><a class="nounderline abstract_t">Arezes J, Foy N, McHugh K, et al. Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia. Blood 2020; 135:547.</a></li><li><a class="nounderline abstract_t">BYRD RB, COOPER T. Hereditary iron-loading anemia with secondary hemochromatosis. Ann Intern Med 1961; 55:103.</a></li><li><a class="nounderline abstract_t">Aleali SH, Castro O, Spencer RP, Finch SC. Sideroblastic anemia with splenic abscess and fatal thromboemboli after splenectomy. Ann Intern Med 1975; 83:661.</a></li><li><a class="nounderline abstract_t">Bottomley SS. Sideroblastic anemia: Death from iron overload. Hosp Pract 1991; 26(suppl 3):55.</a></li><li><a class="nounderline abstract_t">Byrne MT, Bergman AK, Ruiz AI, et al. Postsplenectomy thromboembolic disease in congenital sideroblastic anaemia. BMJ Case Rep 2010; 2010.</a></li><li><a class="nounderline abstract_t">Kakourou G, Vrettou C, Kattamis A, et al. Complex preimplantation genetic diagnosis for beta-thalassaemia, sideroblastic anaemia, and human leukocyte antigen (HLA)-typing. Syst Biol Reprod Med 2016; 62:69.</a></li></ol></div><div id="topicVersionRevision">Topic 7123 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34298585" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316978" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Inheritance of most X-linked traits is not dominant or recessive, just X-linked.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735131" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25705881" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36932887" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Is this really thalassemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34783180" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 36-year-old male with X-linked congenital sideroblastic anemia presenting as chronic microcytic anemia with iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2010494" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hereditary sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : X-linked sideroblastic anemia in ten female probands due to ALAS2 mutations and skewed X chromosome inactivation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24660232" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A double red cells population in a woman with a microcytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477213" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Onset of X-linked sideroblastic anemia in the fourth decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27292130" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lethal ALAS2 mutation in males X-linked sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10029606" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050011" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11843825" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : X-linked cerebellar ataxia and sideroblastic anaemia associated with a missense mutation in the ABC7 gene predicting V411L.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4045952" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10196363" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27488349" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27102574" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A novel mutation in NDUFB11 unveils a new clinical phenotype associated with lactic acidosis and sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34510712" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A phenotypic expansion of TRNT1 associated sideroblastic anemia with immunodeficiency, fevers, and developmental delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166783" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594705" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25957392" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2310696" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Two types of acquired idiopathic sideroblastic anaemia (AISA)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792275" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496230" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Copper deficiency in celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365170" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Copper deficiency after gastric surgery: a reason for caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26060870" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Concurrent copper and iron deficiency in a gastric bypass patient: a great mimicker of MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321896" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anemia after bariatric surgery: more than just iron deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088385" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hypocupremia-related myeloneuropathy following gastrojejunal bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12149237" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Copper deficiency masquerading as myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30742201" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A 54-Year-Old Man With Pancytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4209571" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Manifestations of copper deficiency in a patient with systemic sclerosis on intravenous hyperalimentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8492415" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : [Anemia and neutropenia due to copper deficiency during long-term total parenteral nutrition].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16020879" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical features of hematological disorders caused by copper deficiency during long-term enteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26947425" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Haematogone hyperplasia in copper deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31957894" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The hematological effects of copper deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172183" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874162" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525032" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19732792" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2094240" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11051380" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Zinc-induced copper deficiency in a coin swallower.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19011402" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Zinc toxicity from massive and prolonged coin ingestion in an adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31763583" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pennies for Your Thoughts: A Case Series of Pancytopenia Due to Zinc-induced Copper Deficiency in the Same Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35367442" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The COVID-19 Pandemic and Zinc-Induced Copper Deficiency: An Important Link.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757970" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acquired sideroblastic anaemia induced by a copper-chelating agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3885271" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427906" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : CNS demyelination associated with copper deficiency and hyperzincemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136714" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Myelopathy due to copper deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15762288" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15834043" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007901" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : "Myelodysplasia," myeloneuropathy, and copper deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914761" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Relapsing hypocupraemic myelopathy requiring high-dose oral copper replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5939095" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Iron and folate metabolism in tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184524" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Severe isoniazid related sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31833877" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sideroblastic Anemia Associated With Isoniazid Prophylaxis in a Person Living With HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31833877" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sideroblastic Anemia Associated With Isoniazid Prophylaxis in a Person Living With HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6054596" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pyridoxine-responsive sideroblastic anemia due to antituberculous drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5764031" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Determination of serum and blood pyridoxal phosphate concentrations with purified rabbit skeletal muscle apophosphorylase b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4274683" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Early changes in pyridoxine status of patients receiving isoniazid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4963348" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Reversible sideroblastic anemia caused by chloramphenicol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14284981" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A CONTROLLED DOUBLE-BLIND STUDY OF THE HEMATOLOGIC TOXICITY OF CHLORAMPHENICOL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556031" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15454180" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22120958" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The perils of not digging deep enough--uncovering a rare cause of acquired anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32510577" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Vacuolation of early erythroblasts with ring sideroblasts: a clue to the diagnosis of linezolid toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15059072" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sideroblastic anaemia during fusidic acid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8435326" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7632102" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21818765" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pyrazinamide-induced sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3747828" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Anemia in alcoholics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5545458" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The evolution of anemia in alcoholic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19731322" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21309041" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323989" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mutation spectrum in Chinese patients affected by congenital sideroblastic anemia and a search for a genotype-phenotype relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323989" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mutation spectrum in Chinese patients affected by congenital sideroblastic anemia and a search for a genotype-phenotype relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25064706" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sideroblastic anemia: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14247472" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : SIDEROBLASTS AND SIDEROBLASTIC ANAEMIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7042158" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28072603" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Dyserythropoiesis of myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28495927" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : An infant with Pearson syndrome: a rare cause of congenital sideroblastic anemia and bone marrow failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232625" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Morphologic features of normoblasts in a case of myopathy, lactic acidosis, and sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3064310" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pathophysiology of heme synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30401706" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The molecular genetics of sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33414725" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Genetics and Genomics Approaches for Diagnosis and Research Into Hereditary Anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32557003" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Congenital Anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28222336" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27808451" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ringed sideroblasts inβ-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25064711" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Use of magnetic resonance imaging to monitor iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560104" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8107717" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643445" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051567" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Coenzyme Q is effective on anemia in a patient with sideroblastic anemia and mitochondrial myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37043658" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Luspatercept as Potential Treatment for Congenital Sideroblastic Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37037668" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Management of luspatercept therapy in patients with transfusion-dependentβ-thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29358286" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28040720" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913517" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of low-risk myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222293" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Current treatment algorithm for the management of lower-risk MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31914241" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32089218" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Luspatercept in Myelodysplastic Syndromes: Who and When?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32089218" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Luspatercept in Myelodysplastic Syndromes: Who and When?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35797468" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31558432" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Splicing factor mutant myelodysplastic syndromes: Recent advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1422494" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Congenital sideroblastic anemia successfully treated by allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886220" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11442487" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12774059" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16540426" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553769" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30214775" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Reduced-toxicity allogeneic hematopoietic stem cell transplantation in congenital sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36457748" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Case report: An infant boy with X-linked sideroblastic anaemia successfully treated by umbilical cord blood haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36757170" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Allogenic Hematopoietic Stem Cell Transplant in Iranian Patients With Congenital Sideroblastic Anemia: A Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36729249" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36729249" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20467559" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Iron Loading and Overloading due to Ineffective Erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6134064" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Iron overload in mild sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6130377" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Iron overload in mild sideroblastic anaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16540354" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Disparate phenotypic expression of ALAS2 R452H (nt 1407 G --&gt;A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21647608" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Need for early recognition and therapeutic guidelines of congenital sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : The spectrum and role of iron overload in sideroblastic anemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/935887" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Effect of pyridoxine plus chronic phlebotomy on the function and morphology of bone marrow and liver in pyridoxine-responsive sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34617272" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32089223" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203980" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31899794" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13689579" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Hereditary iron-loading anemia with secondary hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1200498" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Sideroblastic anemia with splenic abscess and fatal thromboemboli after splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Sideroblastic anemia: Death from iron overload</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22778251" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Postsplenectomy thromboembolic disease in congenital sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26636621" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Complex preimplantation genetic diagnosis for beta-thalassaemia, sideroblastic anaemia, and human leukocyte antigen (HLA)-typing.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
